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Abstract

Thrombin Activatable Fibrinolysis Inhibitor (TAFI), encoded by CPB2, cleaves
carboxyl-terminal lysine residues from partially degraded fibrin, thus assisting in the
attenuation of fibrinolysis. The finding of several new alternatively spliced (AS) CPB2
variants within numerous cell types suggests that AS is an important mechanism
regulating CPB2 gene expression. This thesis investigated the extent of AS events
occurring in various vascular and immune cells, and identified proteins translated from
AS CPB2 mRNA. To determine whether a minigene approach could be used to model the
cell-specific AS pattern that occurs endogenously, two minigene constructs were created.
Real time RT-PCR analysis revealed that the pattern and extent of AS varies in a cellspecific manner. However, the minigenes were found to be unable to recapitulate the cellspecific splicing pattern of CPB2 that occurs endogenously. Metabolic labeling in
conjunction with immunoprecipitation resulted in the detection of the Δ7 TAFI variant
retained within HepG2 cells.
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I am among those who think that science has great beauty.
A scientist in his laboratory is not only a technician: he is also a child placed before
natural phenomena, which impress him like a fairy tale.

- Marie Curie
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Chapter 1: Introduction

1.1 Coagulation, Fibrinolysis and TAFI as a Molecular Link

Maintenance of the fluidity of blood within the vasculature is a key factor required for
survival by multicellular organisms (1). Trauma induces the hemostatic response to
reduce the probability of death by hemorrhaging (2). The first step in the hemostatic
response is the formation of the platelet plug, via platelet adhesion, activation and
aggregation (2). Following the initial platelet plug formation, the coagulation pathway is
activated and results in the production of fibrin, which helps to maintain the structure and
integrity of the blood clot (1). Subsequently, the fibrinolytic pathway is initiated to
remove the clot after the damage at the vessel wall has been repaired (1). The balance
between the deposition and the removal of fibrin is crucial to the maintenance of
hemostasis within the organism (1). Imbalances in the functioning of either pathway can
lead to various pathological disorders, such as an increased risk of thrombosis or bleeding
(1). Thus, precise regulation of these pathways as well as communication between them
is key for survival.
Endothelial cells play an important role in separating the tissues from the dynamic
environment occurring within the bloodstream (3). Platelets are cell fragments that are
produced by megakaryocytes of the bone marrow and then released into the bloodstream
(3). There, they play an important role in surveying the endothelium for lesions (3).
Under normal circumstances, circulating platelets do not adhere to the endothelial cells of
the vasculature (3). However, when a breach in the integrity of the vasculature ensues,
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three important successive events must occur before the coagulation cascade is initiated,
which include: platelet adhesion, platelet activation and platelet aggregation (4).
Trauma induced rupture of the endothelium results in the exposure of subendothelium collagen (2). Neighboring intact endothelial cells trigger the release of von
Willebrand factor (vWf), a multimeric glycoprotein that attaches to the collagen via a
glycoprotein anchor (2). Circulating platelets are attracted to the collagen-vWf complex,
and bind to it through glycoprotein Ib on the surface of platelet membranes (2). Platelet
adhesion results in the activation of the platelets and subsequent release of the contents of
their intracellular granules (2). Release of Adenosine Diphosphate (ADP) causes the
platelets to undergo a morphological change in shape, as well as release of Thromboxane
A2, (TXA2) (2). TXA2 leads to the increased recruitment of circulating platelets to the
site of injury, and subsequent adherence and activation of these platelets to form the
primary hemostatic structure, the platelet plug (2). Activated platelets also release large
stores of intracellular calcium, which are required for several reactions in the coagulation
cascade (2). Lastly, activated platelets undergo a conformational rearrangement of their
surface membrane phospholipids (4). Phosphatidylserine is exposed on the platelet
surface, and helps facilitate the binding of coagulation cascade cofactors, Factor V, and
Factor VIII to the platelet surfaces (4).
Once the initial platelet plug is formed, the coagulation cascade (Figure 1.1) is
activated when an endothelial cell membrane bound protein, Tissue Factor (TF), is
exposed to flowing blood (5). TF binds Factor VII within the plasma, and activates it to
Factor VIIa (5). When TF concentrations are high, this complex (TF-VIIa) has the ability
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Image Adapted From:
Bodary, P.F., Wickenheiser, K.J., Eitzman, D.T. Recent Advances in Endogenous Fibrinolysis:
Implications for Molecular-Based Treatment of Vascular Disorders. Expert Reviews in Molecular
Medicine, 2002; 4: 1-10.

Figure 1.1 Coagulation and Fibrinolytic Pathways with TAFI as a Molecular Link
A. The coagulation cascade is activated upon injury to the endothelial vessel wall, which
results in the exposure of Tissue Factor (TF) to the bloodstream. Circulating Factor VII
will bind TF to become activated Factor VII, VIIa. On the surface of activated platelets,
Factor X is activated (Xa), which will go on to activate the zymogen prothrombin to
thrombin. Thrombin will convert soluble fibrinogen to insoluble fibrin, which will help
strengthen the initial blood clot formed by the aggregation of platelets at the site of vessel
injury.
B. Plasmin-mediated fibrinolysis is induced following the activation of plasminogen to
plasmin via tissue-type plasminogen activator (tPA). Plasmin cleavage of the thrombus
results in clot lysis and subsequent fibrin degradation products (FDPs). Plasminogen
activator inhibitor 1 (PAI-1) inhibits the activation of plasminogen to plasmin by
inhibiting tPA. α-2-Antiplasmin (α-2-AP) binds free circulating plasmin and inactivates
it, thus inhibiting clot lysis. Thrombin Activatable Fibrinolysis Inhibitor (TAFI) cleaves
carboxyl-terminal lysine residues on partially degraded fibrin, thus inhibiting the binding
of tPA and plasminogen to the fibrin surface for plasminogen activation to plasmin.
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to activate Factor X to Factor Xa on the surfaces of activated platelets (5). In the presence
of calcium and negatively charged phospholipids (such as on the surface of activated
platelets), Factor Xa, along with its cofactor Factor Va, results in the formation of
thrombin from the inactive zymogen, prothrombin. Thrombin activation is a key step in
the coagulation cascade, and results in the conversion of soluble fibrinogen into insoluble
fibrin. Insoluble fibrin strands helps to stabilize the initial blood clot formed by the
aggregation of platelets at the site of vessel injury.
Once fibrin has been produced, the fibrinolytic pathway is initiated (6) (Figure 1.1).
Plasmin is a serine protease capable of cleaving fibrin strands into fibrin degradation
products (FDPs). Plasmin is formed from cleavage of the zymogen plasminogen by
tissue-type plasminogen activator (t-PA). In the absence of fibrin, t-PA is an extremely
inefficient activator of plasminogen. Fibrin acts a cofactor to bind both of these
components to stimulate plasminogen activation, hence localizing biologically significant
plasminogen activation to where it is required (7). Plasmin activity is countered by the
presence of fast-acting serpin inhibitors, principally antiplasmin.
Since plasmin cleaves polypeptides after basic residues, limited cleavage of fibrin
results in the formation of a form of fibrin containing carboxyl-terminal lysine residues
(fibrin’) (Figure 1.1). These residues serve as binding sites for plasminogen and t-PA,
thereby accelerating the rate of plasmin formation and leading to positive feedback in the
fibrinolytic cascade (7). The carboxyl-terminal lysine residues also promote another
positive feedback step in fibrinolysis, the plasmin-mediated conversion of native Gluplasminogen to Lys-plasminogen, which binds fibrin more avidly and which is a better
substrate for t-PA (7). The carboxyl-terminal lysines also bind to plasmin and hence
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protect the enzyme from consumption by antiplasmin (7). Altogether, the various positive
feedback loops in the fibrinolytic cascade result in increased production of plasmin,
ultimately leading to dissolution of the fibrin clot (8).
A key regulator and intermediary between the coagulation and fibrinolytic pathways
is Thrombin-Activable Fibrinolysis Inhibitor, TAFI. Activated TAFI (TAFIa) cleaves
carboxyl-terminal lysine and arginine residues from fibrin’, which results in decreased
binding sites available for plasminogen and t-PA to bind to the fibrin’ surface (9) (Figure
1.1). This results in the inhibition of positive feedback in the fibrinolytic cascade with
reduced plasmin formation, thus attenuating the lysis of the blood clot. Therefore, TAFI
is a direct link between the coagulation and fibrinolytic pathways, and performs a key
regulatory function in the removal of the fibrin clot (10).

1.2 CPB2, The Gene Encoding TAFI

The human gene encoding TAFI is CPB2 (Carboxypeptidase B2 by the Human
Genome Organization (HUGO)), and is located on chromosome 13 (13q14.11) (11). The
gene spans 48 kb of genomic DNA, and has 11 exons and 10 introns (12). The position of
the exon/intron boundaries established in CPB2 were found to be the same as in the genes
that TAFI is evolutionarily related to, such as the pancreatic and mast cell
carboxypeptidases (13).
Characterization of the 5’ flanking region of the CPB2 gene resulted in identification
of the promoter, which lacks a consensus TATA sequence (12). Accordingly, several
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transcription initiation sites were identified in liver, which is the site of expression of
CPB2 leading to secretion of TAFI into plasma. Based on which transcription initiation
start site is used, various CPB2 transcripts exist with 5’ untranslated regions (5’-UTR)
ranging from 9 to 46 bps in length (12). Through successive deletions of the human
CPB2 promoter, a 70 bp sequence was identified between -141 and -72 that is required
for the liver specific expression of CPB2 (12). Deletion of this sequence within the CPB2
promoter was found to eliminate the expression of a reporter gene driven by the CPB2
promoter in Hepatocellular carcinoma cells (HepG2) (12).
Our lab has extensively studied the proximal region of the CPB2 promoter
between nucleotides -424 and +16. Multiple liver transcription factor binding sites were
discovered using in vitro DNaseI footprinting, and are designated Site A through Site J,
with Site A proximal to the initiator methionine sequence (14). Analysis of these sites
revealed that CCAAT/-enhancer binding protein (CCAAT/EBP) binds at Site A, Nuclear
Factor –Y (NF-Y) binds at Site B, and Glucocorticoid Receptor (GR) binds the
Glucocorticoid Response Element (GRE) at Site C (15, 14, 16). Furthermore, Hepatic
Nuclear Factor-1 (HNF-1) was also found to bind in the region midway between Site B
and Site C (14). All of these transcription factor binding sites are important for the liver
specific expression of CPB2, with the exception of the GRE, which mediates increased
CPB2 transcription in response to the synthetic glucocorticoid dexamethasone (16).
To date, there are 19 single nucleotide polymorphisms (SNPs) documented within
CPB2 (1). There are ten SNPs located within the 5’ flanking region, six within the coding
region and three within the 3’ flanking region (1). With respect to the SNPs found within
the 5’-UTR, none have been shown to have a significant effect on the activity of the
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CPB2 promoter (17). Of the six within the coding region, only two result in an amino
acid substitution. At nucleotide position +505, an adenine substitution for a guanine
results in an alanine substitution for a threonine at amino acid position 147 (18). At
nucleotide position +1040, a cytosine substitution for a thymine results in a threonine
substitution for an isoleucine at amino acid position 325 (19). The amino acid substitution
at position 147 was found not to have an effect on TAFI activation, TAFIa stability or
antifibrinolytic activity of TAFI (18). However, the Ile substitution at 325 resulted in a
two-fold more stable form of TAFIa at 37°C than the variant containing Thr. The Ile325
variant thus has a greater antifibrinolytic effect (20).
Examination of the 3’-untranslated region (3’-UTR) of the CPB2 mRNA resulted
in the discovery of three different polyadenylation sites, which are located at +1677,
+1710 and +1836, yielding 3’-UTR’s of the following lengths: 390, 423, and 549
nucleotides, respectively (12, 21). Our laboratory has shown that the length of the 3’UTR determines the stability of the mRNA transcript, with the stability of the transcript
decreasing as the length of the 3’-UTR increases (21). The half-lives of the CPB2
transcripts, from shortest to longest, were determined to be: 5.1 hours, 3.3 hours, and 2.6
hours (21). Furthermore, we have also demonstrated that the rate of usage of each
polyadenylation site can be modified through the treatment with various cytokines (21).
Treatment of HepG2 cells with interleukins 1β (IL-1β) and interleukin 6 (IL-6) in
combination results in a 2-fold decline in the stability of the transcript, as well as a 60%
reduction in the mRNA abundance (16). With respect to usage of each polyadenylation
site without cytokine treatment, it was found that the first polyadenylation site was
determined to be used 28 times more frequently than the last polyadenylation site, and the
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second polyadenylation site was utilized three times more frequently than the last
polyadenylation site (21). In addition, it was also noted that under cytokine treatment, the
longest transcript, which normally accounts for less than 1% of the total polyA forms,
became the dominant transcript under these conditions (21). Therefore, the decrease in
mRNA abundance that is observed with this treatment is attributable to a shift in use of
polyadenylation sites, which selects for the most unstable transcript, as well as specific
destabilization (2-fold decrease in half-life) of the longest and most unstable transcript
(21).
One very well established class of instability elements within the 3’-UTR of an
mRNA transcript is the A/U rich elements. A/U rich elements are generally 50 to 150
base pairs in length, are rich in U nucleotides, and can either contain multiple copies of
the pentameric sequence, AUUUA, or the nonameric sequence, UUAUUUAUU. The
TAFI 3’-UTR has been found to contain one pentameric sequence, AUUUA, at
nucleotide +1325, and is fairly A/U rich in content as well (21).
In a subsequent study conducted by our laboratory, cis-acting elements were
found in the 3’-UTR of CPB2 mRNA (22). One stability and three instability elements
were identified. In the segment common to all three transcripts lies the stability element
and also one of the three instability elements. The second instability element lies between
the first and the second polyadenylation site, and the third instability element lies
between the second and the third polyadenylation site. Furthermore, gel mobility shift
assays and bioinformatic analysis revealed that tristetrapolin (TTP) is a trans-acting
factor protein that could bind at nucleotides +1668 to +1677 in the 3’-UTR of CPB2
mRNA. Tristetrapolin is a zinc finger RNA binding protein capable of destabilizing
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mRNA transcripts by encouraging deadenylation of the polyA tail of the transcript (23).
An RNA radiolabeled probe that contained a mutated TTP binding site resulted in
increased stability of a β-globin CPB2 fusion transcript. In addition, knockdown of TTP
in the presence of a β-globin CPB2 fusion transcript with an intact TTP binding site also
resulted in increased stability of a β-globin CPB2 transcript (22). Together these results
indicate that TTP is an important trans-acting factor protein that can negatively regulate
CPB2 mRNA transcript stability (22).

1.3 TAFI Protein

Four different research groups independently discovered TAFI between 1989 and
1995; hence it is also known as procarboxypeptidase U (due to its intrinsic instability)
(24), procarboxypeptidase R (because it appeared to prefer carboxyl-terminal arginine
resides) (25), plasma procarboxypeptidase B (due to its similarity to pancreatic
carboxypeptidase B) (26), and TAFI (because it could inhibit fibrinolysis after activation
by thrombin) (27).
The plasma pool of TAFI is synthesized within the liver as a pre-pro-peptide of 423
amino acids (26). Upon secretion from the cell, the amino-terminal signal peptide of 22
amino acids is cleaved off to form the mature TAFI zymogen, which is 401 amino acids
in length (26). The mature TAFI protein consists of two domains: an activation peptide
(92 amino acids in length) and a catalytic domain (309 amino acids in length). Although
the predicted molecular weight of TAFI is 46 kDa, TAFI has four sites for addition of N-
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linked glycans and therefore migrates on sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) at ~ 60 kDa (28, 26). The four glycosylation sites are
located within the activation domain (Asn22, Asn51, Asn63, Asn86), and are always
glycosylated (27).
TAFI can be activated through proteolytic cleavage at Arg92, by thrombin, plasmin, or
thrombin in complex with thrombomodulin (28, 26, 29). Activation of TAFI results in the
release of the activation peptide from TAFI to form the active enzyme, TAFIa, which
consists of 309 amino acids and migrates on SDS-PAGE at approximately 35 kDa (30).
Thrombin and plasmin are relatively weak activators of TAFI, requiring large amounts of
each enzyme, as well as long incubation periods with TAFI (30). However, activation of
TAFI by thrombin in complex with the endothelial cell receptor thrombomodulin, results
in over a 1000-fold increase in the rate of TAFI activation (29). Thus, thrombin in
complex with thrombomodulin is thought to be the main physiological activator of TAFI
(29). It is also important to note that glycosaminoglycans can accelerate TAFI activation
by plasmin up to 20-fold (31).
TAFIa has basic carboxypeptidase activity: it cleaves carboxyl-terminal lysines and
arginines from TAFIa substrates such as partially-degraded fibrin. The ability of TAFIa
to attenuate clot lysis occurs through a threshold-dependent mechanism (32, 33). If the
TAFIa concentration remains above its threshold it can effectively slow down the
conversion of plasminogen to plasmin, and thus increase clot lysis time. However, as
soon as the TAFIa concentration falls below its threshold, fibrinolysis rate is accelerated.
The TAFIa threshold value is dependent on the following factors: rate at which TAFI is
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converted to TAFIa, the intrinsic instability of TAFIa, concentration of plasmin activators
(t-PA), and plasmin inhibitors (antiplasmin).
Currently, there is no known physiological inhibitor of TAFIa in plasma (34).
However, TAFIa activity can be regulated through its own intrinsic instability (35). The
half-life of TAFIa is 8 (Thr325) or 15 (Ile325) minutes at 37°C, 45 minutes at 30°C, and
several hours at 22°C (30). The intrinsic instability of TAFIa is mediated through a
conformational change, which causes the protein to unfold (36). It has been demonstrated
that the antifibrinolytic potency of TAFIa is directly related to its half-life (35) indicating
that its conformational instability is the physiological mechanism by which TAFIa
activity is controlled. Upon unfolding, several previously cryptic cleavage sites become
available for proteolytic cleavage by thrombin at Arg302, or by plasmin at Lys327 or Arg330
(37). Although the spontaneous unfolding of TAFIa is not thought to be reversible, these
cleavages would certainly inactivate TAFIa. Moreover, there is evidence that plasmin can
cleave TAFIa even in the absence of the conformational change (36).
Due to the zinc ion present in the active site of TAFIa, TAFIa is also sensitive to
inactivation by chelating agents, such as o-phenantroline, and ethylenediaminetetraacetic
acid (EDTA) (38). TAFIa can also be inhibited by small synthetic inhibitors such as the
lysine analogue epsilon aminocaproic acid (ε-ACA) (28, 30) and the arginine analogues
2-guanidinoethylmercaptosuccinate (GEMSA) (30) and DL-2-mercaptomethyl-3guaninoethyl-thio-propanoic acid (MERGEPTA), reducing agents such as dithiothreitol
(DTT) and 2-mercaptoethanol (BME), and naturally occurring inhibitors in the potato
(potato tuber carboxypeptidase inhibitor; PTCI) (39) and leech Hirudo medicinalis (leech
carboxypeptidase inhibitor; LCI) (40).
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1.4 Case Studies: Imbalances in TAFI and the Risk of Atherothrombotic Disease

Normally, a fine balance exists between the coagulation and fibrinolytic systems
within the body. Changes within either cascade can result in an increased tendency to
bleed or an increased susceptibility to ongoing thrombotic events (1). The formation of
excessive thrombi can cause heart attacks or strokes. TAFI plays an important regulatory
role in maintaining the balance between these two systems, and thus may serve as an
important risk factor in the development of atherothrombotic disease. Currently, the role
of TAFI in atherothrombotic diseases is unclear. However, it is postulated that elevated
levels of TAFI may be linked to an increased risk for atherothrombotic disease.
Various assays have been developed in order to measure the different forms of
TAFI. Due to the potential role of TAFI as a risk factor in atherothrombotic disease,
several studies have measured the plasma TAFI concentration in healthy individuals in
order to determine a baseline reference value. From these studies, it was found that the
plasma TAFI concentration within the human population falls within the range of 73 –
275 nM (41, 42, 43). Thus, the plasma TAFI antigen levels in healthy individuals display
a large amount of variability between individuals (42). Even within different ethnic
groups, there are significant differences in the plasma TAFI levels observed. For
instance, TAFI antigen levels were found to be significantly lower in a black African
male group in comparison to age-matched Caucasian males (44).
Hence, many studies have been aimed at deducing the factors that contribute to
the great diversity observed in plasma TAFI antigen levels in the human population.
Besides environmental factors, heritable genetic factors have been an important area of
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study. Polymorphisms within the 5’-UTR were shown not to affect CPB2 promoter
activity and thus had no direct effect on CPB2 gene expression (13). Also,
polymorphisms within the 3’-UTR could affect CPB2 mRNA transcript stability and thus
mRNA abundance (13). Each of the three polymorphisms in this region were discovered
to influence CPB2 mRNA stability in a manner partially in agreement with the effects of
these polymorphisms on plasma concentrations of TAFI (17). Amino acid substitutions
within the coding region could result in altered rates of TAFI protein synthesis or TAFI
protein secretion from the cell (13), although this has yet to be documented directly.
Thus, the CPB2 genotype can affect the plasma TAFI antigen levels one possesses, and
studies have investigated how both of these factors contribute to an individual’s risk of
developing atherothrombotic disease.
In a study conducted by Juhan-Vague and coworkers (45), the relationship
between plasma TAFI antigen levels and the presence of traditional cardiovascular risk
factors was examined. Six hundred twenty six patients participating in primary
prevention of coronary heart disease (CHD) at a metabolic ward were assessed for family
history of heart disease, smoking use, drug use, alcohol consumption, hormonal therapy,
body mass index, waist-to-hip circumference ratio, plasma lipids, diabetes, blood
pressure, and physical activity level. In this study, they found TAFI antigen levels were
associated with age in women, but not in men. Also, traditional cardiovascular risk
factors were only able to explain a small proportion of the variability in plasma TAFI
levels observed in this study group. Waist-to-hip circumference ratio accounted for 2% of
the variability in plasma TAFI antigen levels in men, and 3% of the variability in plasma
TAFI antigen levels in females. Thus, from this study it was concluded that traditional
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cardiovascular risk factors, which can be indicative of environmental influences on an
individual, play only a minor role in determining plasma TAFI antigen levels and that
genetic influences may be involved.
In a study by Henry and coworkers (46), seven novel SNPs were discovered
within the CPB2 gene, five in the 5’ flanking region: -2599 G/C, -2345 2G/1G, -1690
G/A, -1102 T/G and -438 A/G, and two in the 3’ flanking region: +1542 C/G and +1583
A/T, by thorough screening of 40 healthy individuals. All of the SNPs identified were
found to be in strong linkage disequilibrium with each other, as well as with the SNP in
the coding region, Ala147Thr, previously identified by Zhao and coworkers in 1998.
Furthermore, all of the SNPs were found to be correlated with plasma TAFI antigen
levels, and overall, were responsible for 20-52% of the variability in plasma TAFI
antigen levels. This was the first study to show that genetic polymorphisms within the
CPB2 gene could influence plasma TAFI antigen levels, which was previously postulated
by Juhan-Vague in 2000 (45).
Moreover, another study by Franco and coworkers (47) also investigated the 5’
flanking region of the CPB2 gene for SNPs and their relationship to plasma TAFI antigen
levels. By sequencing the 5’ flanking region, they found seven SNPs: three that were
previously characterized by Henry and coworkers (46) (-1690 G/A, -1102 T/G and -438
A/G) and four novel SNPs (-1925 T/C, -1053 T/C, -530 C/T and -152 A/G). They found
that -152 A/G, -530 C/T, -1925 T/C were in strong linkage disequilibrium with each
other, and that -438 A/G, -1053 T/C, - 1102 T/G, and -1690 AA were in strong linkage
disequilibrium with each other. Five of the seven SNPs were found to be in close
proximity to several established transcription factor-binding sites within the 5’ flanking
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region of CPB2. Thus, it was postulated that the SNPs might influence plasma TAFI
antigen levels through transcription regulation processes. With respect to plasma TAFI
antigen levels, -438 GG/ -1053 CC/ -1102 GG/ -1690AA homozygotes were found to
have the highest plasma TAFI antigen levels versus heterozygotes (-438 AG/ -1053TC/ 1102 TG/ -1690 GA), and homozygotes (-438 AA/ -1053TT/ -1102TT/ -1690GG), the
latter of whom had the lowest plasma TAFI antigen levels. These findings further
supported the study by Henry and coworkers (46), who established that plasma TAFI
antigen levels were, at least in part, under genetic control.
Furthermore, Brouwers and coworkers (19), identified a novel SNP within exon 9
of the coding region, +1040 C/T, which results in a threonine for isoleucine amino acid
substitution at position 325 of the protein. Genotype and allele frequency analysis of 152
healthy blood donors determined that the +1040 CC (325Thr/Thr) genotype correlated
with the highest plasma TAFI antigen levels while the +1040 TT (325Ile/Ile) genotype
correlated with the lowest. Further characterization led to the discovery that the Ile325
TAFIa isoform had a half life of 16 minutes, in comparison to wild type TAFIa, which
has a half life of 8 minutes (48). Thus, this SNP results in a TAFIa isoform that is twice
as stable at body temperature, and therefore has the potential for greater anti-fibrinolytic
activity. However, the +1040 TT genotype encoding the more stable Ile325 variant is also
associated with the lowest plasma TAFI antigen concentrations, which may cancel out
the effect of stability on antifibrinolytic potential. With respect to the other SNP-encoded
amino acid substitution within the coding region, Ala147Thr, functional analysis
determined that this amino acid substitution was found not to affect the ability of the
TAFI isoform to become activated, or function as a basic carboxypeptidase B (18).
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In a later study by Morange and coworkers (49) the association between CPB2
gene polymorphisms and risk of CHD was investigated. A total of six of the previously
characterized SNPs were examined, two within the 5’-UTR (-2599 G/C and -438 A/G),
two within the coding region (Ala147Thr and Thr325Ile), and two within the 3’-UTR
(+1542 G/C and +1583 A/T), for their correlation to plasma TAFI antigen levels. It was
discovered that 20% of the variability in plasma TAFI concentration within the
population is due to SNPs within the CPB2 gene. This further supports the earlier study
by Henry and coworkers (46), who found that SNPs within the CPB2 gene could explain
between 20-52% of the variation in plasma TAFI concentration. However, none of the
SNPs investigated were found to contribute to a greater risk of CHD. An important
implication from this study is that only a fraction of the variation in plasma TAFI
concentrations can be attributed to genetic factors; thus, the remainder of the variation
arises from non-genetic factors such as regulation of CPB2 gene expression by external
stimuli.
In a study conducted by van Tilburg and coworkers (50) the connection between
elevated plasma TAFI antigen levels and a first incidence of deep vein thrombosis (DVT)
was investigated in a large population-based control study, with 474 age and sex matched
subjects. The effect of sex, age, and oral contraceptive use on plasma TAFI concentration
levels was examined, as well as the relationship between elevated TAFI levels and other
coagulation factors. From this study, it was determined that 14% of patients with a first
deep vein thrombotic event had TAFI antigen levels greater than the 90th percentile, in
comparison to controls, which only 9% had TAFI antigen levels greater than the 90%
percentile. In men, there was no correlation found between elevated TAFI levels and risk
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for thrombosis. However, in women, an age-dependent increase was observed.
Furthermore, elevated plasma TAFI levels were also observed amongst women between
the ages 31-50 who used oral contraceptives, in comparison to those who did not. With
regard to other coagulation factors, patients with TAFI levels above the 90th percentile
were also found to have elevated thrombin levels, which is a known activator of TAFI.
From this study, it was concluded that elevated TAFI antigen levels above the 90th
percentile increased the risk for a first deep vein thrombotic event by two-fold.
In a second study conducted by Eichinger and coworkers (51) the association
between elevated TAFI levels and risk for recurring venous thromboembolism was
investigated. Six hundred patients with a first spontaneous venous thromboembolism
were entered into this study. Plasma TAFI antigen levels were measured via the
ImuClone TAFI enzyme linked immunosorbent assay (ELISA). In this study, they found
that patients who had TAFI levels above the 75th percentile had a 14.5% probability of
recurrence of venous thromboembolism, in comparison to 6.8% found in patients with
TAFI levels below the 75th percentile. From this study, it was concluded that high TAFI
levels increased the risk of recurrent venous thromboembolism nearly two-fold as well.
Furthermore, in a study conducted by Santamaria and coworkers (52) high
functional TAFIa levels were correlated with an increased risk for ischemic stroke. In this
study, functional TAFIa activity was examined in 114 patients who had experienced at
least one ischemic stroke event in comparison to age-and sex-matched controls with no
history of arterial disease. Blood was taken from subjects approximately one month after
the initial stroke event, and TAFIa activity was measured after activation by thrombinthrombomodulin in the presence of a synthetic substrate, hippuryl-arginine. It was found
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that TAFIa levels were significantly higher in patients with ischemic stroke, in
comparison to controls. Sex or age of the subject were both found not to be significant
factors with respect to variation in TAFIa levels and risk of ischemic stroke. However, it
was found that patients with a family history of arterial disease did have higher TAFIa
levels in comparison to subjects without a family history. Overall, from this study, it was
concluded that increased levels of functional TAFIa in subjects with a history of arterial
disease increases the risk of ischemic stroke by six-fold.
In a second study conducted by Leebeek and coworkers (53) the association
between elevated functional TAFI levels and incidence of a first only ischemic stroke
event was investigated. In this study, 124 patients with a recent first ischemic stroke
event were compared to age-and sex-matched controls. Blood was taken from patients
within two weeks of the initial stroke event, and risk factors, such as smoking,
hypertension, diabetes, hypercholestemia, use of oral contraceptives, positive family
history and previous DVT were assessed. Functional TAFIa levels were measured via a
functional assay, the clot lysis assay (54). In this study, they found that patients with
ischemic stroke had prolonged clot lysis times, which is indicative of elevated TAFIa
levels. In addition, factors found not to affect TAFIa levels in ischemic stroke patients
included gender, diabetes, and smoking. However, hypertension, hypercholestemia, and
age (>45 years) were found to be present in patients with ischemic stroke and increased
TAFIa levels. Moreover, in a three-month follow-up, 36 patients out of the 124 were
randomly selected, and TAFIa levels were re-measured. TAFIa levels were found to be
consistently high in this subset, and thus it was concluded that increases in TAFIa levels
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are not due to an acute phase response. From this study, it was also concluded that
increased TAFIa levels are correlated with an elevated risk of ischemic stoke.
In a third study conducted by Ladenvall and coworkers (55), they examined the
association between TAFI and ischemic stroke in more depth. Due to the diverse nature
of stroke, and the various stroke subtypes, they employed a large population study
including 600 white age-and sex-matched individuals, with one of five possible stroke
sub-type classifications. Blood was taken from individuals at two time points: once
within ten days of the initial stroke event and once at a three-month follow-up. Intact
plasma TAFI levels and released TAFI activation peptide (TAFI-AP) levels were
measured via sandwich ELISAs (56). In this study, they found that ischemic stroke
patients of all subtypes had elevated intact TAFI and released TAFI-AP levels in
comparison to controls. Furthermore, it was discovered that released TAFI-AP levels
were higher at the three-month follow up in comparison to the initial measure. This study
further supported the previous study completed by Leebeek and coworkers (53) that
showed that elevated TAFI levels are associated with ischemic stroke, but this occurrence
is not due to an acute phase response.
In addition, in a study conducted by de Bruijne and coworkers (57), TAFI levels
and their connection to arterial thrombosis were evaluated. 327 patients (ages 18-45 for
males or 18-55 for females) with a single CHD or ischemic stroke event were compared
to 332 healthy controls. Only relatively young subjects were included since they would
be expected to have minimal atherosclerosis, which would allow the researchers to
investigate other possible risk factors contributing to cardiovascular disease development
such as thrombophilia. Also, patients were only included if the event had occurred at least
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one month prior to the study to exclude the possibility of elevated TAFI levels arising
from an acute phase response. Intact plasma TAFI, released TAFI-AP, and inactive
TAFIa (TAFIai) were all measured using three different sandwich ELISAs (56); TAFIa
activity was also measured via a clot lysis assay. It was found that TAFIai levels were
higher in both patient groups (i.e. CHD and ischemic stroke patients), in comparison to
healthy controls. However, intact plasma TAFI, released TAFI-AP levels, and TAFIa
activity were found to be similar between patients and controls, which is in contrast to the
previous study, conducted by Ladenvall and coworkers (55), who reported elevated
released TAFI-AP levels in patients with ischemic stroke. However, with respect to the
CHD subgroup only, plasma levels of intact TAFI were also found to be elevated in
comparison to controls. Furthermore, this study also investigated the role of SNPs within
the CPB2 gene on plasma TAFI concentration and its association with arterial
thrombosis. They found that individuals who are homozygous for the Ile325 isoform of
TAFI had lower TAFI levels and a reduced risk for arterial thrombosis. Thus, from this
study, it was concluded that young CHD and ischemic stroke patients had elevated
TAFIai levels, and that individuals homozygous for the Ile325Ile SNP had a protective
advantage against arterial thrombosis.
In a study conducted by Santamaria and coworkers (58), risk of acute coronary
artery disease (CAD) was examined in 174 acute CAD patients in comparison to 211
controls with respect to TAFIa activity. They found that TAFIa activity levels were
higher in patients with CAD compared to controls, and that individuals with high TAFIa
levels had a four-fold increased risk of developing CAD compared to healthy controls.
Interestingly, they also found no correlation between TAFIa levels and traditional
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cardiovascular risk factors, as was previously reported by Juhan-Vague, and coworkers
(45). However, in a later study by Meltzer and coworkers (59), TAFIa activity levels
were examined for correlation to risk of myocardial infarction (MI). TAFIa levels were
measured in 554 men with a first incidence of MI in comparison to 643 healthy controls.
They found that individuals in the first quartile (i.e. having the lowest TAFIa levels) had
a 3.4-fold increased risk of MI in comparison to individuals in the third quartile, who had
a 2.4-fold increased risk of MI. This result is in contrast to the previous study by
Santamaria and coworkers (58) who found a four-fold increased risk of CAD in
individuals who had elevated concentrations of TAFIa.
In a later study conducted by de Bruijne and coworkers (60), the role of TAFI in
young patients with peripheral arterial disease (PAD) was assessed. Forty-seven patients
aged 21-55 with a first indication of PAD and 141 healthy controls were included in this
study. Intact plasma TAFI, released TAFI-AP and TAFIai were measured in patients and
controls using sandwich ELISAs (56). In addition, functional TAFI, TAFIa was measured
via clot lysis assay (54). Intact plasma TAFI antigen levels were found to be significantly
higher in patients with PAD in comparison to controls. Risk of PAD was found to
increase by 18% in PAD patients with every 10% increase in intact plasma TAFI antigen
levels. Released TAFI-AP and TAFIai were found not to be significantly different with
respect to patients and controls. Also, levels of TAFIa were found to be marginally higher
in patients with PAD, although this difference was not statistically significant. From this
study, it was concluded that high intact TAFI plasma antigen levels are associated with
increased risk of developing PAD.
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In a study conducted by Jood and coworkers (61), the association between TAFI
levels and risk of a future atherothrombotic event and/or death was investigated. Intact
TAFI plasma levels and released TAFI-AP were measured in 517 patients three months
after they experienced an acute ischemic stroke via sandwich ELISA (56). The survival
rate of the patients two years after recruitment into the study was then analyzed.
Composite endpoints for patients were defined as death, fatal or non-fatal recurrent
stroke, transient ischemic attack (TIA), and coronary event (CE). At follow-up, 37
composite endpoints had occurred and it was found that patients who had experienced a
composite endpoint had elevated released TAFI-AP levels. However, no statistically
significant correlation was found between intact plasma TAFI levels and patients who
developed a composite endpoint. Furthermore, the released TAFI-AP/intact TAFI ratio
was assessed for its potential to predict the risk of developing a future composite
endpoint. Unfortunately, no correlation was observed between the released TAFIAP/intact TAFI ratio and composite endpoint. Thus, from this study it was shown that
increased levels of released TAFI-AP but not intact TAFI correlated to an increased risk
for a future atherothrombotic event and/ or death in ischemic stroke survivors.
Taken together, the studies surrounding the question of whether or not TAFI is an
important risk factor for atherothrombotic disease are somewhat contradictory. Some
important factors to consider when analyzing results from prior clinical studies include:
the method used to measure TAFI, which TAFI isoform was measured, and whether the
study took into account CPB2 genotype. One of the main methods used to measure TAFI
levels in the population are ELISAs (62). ELISAs utilize TAFI-specific antibodies in
order to capture and measure TAFI antigen levels in a plasma sample. However, in a
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study conducted by Gils and coworkers (63), 27 monoclonal antibodies were tested for
their reactivity to the different forms of TAFI (intact TAFI, released TAFI-AP, and
TAFIai). It was found that all the antibodies tested had different reactivities towards the
different forms of TAFI. Some of the antibodies only reacted with the inactive zymogen,
while others reacted with the inactive zymogen, activated enzyme peptide, as well as the
inactivated enzyme forms. In addition, they also found that some of the commercially
available ELISA kits had a partial dependence on the Thr/Ile325 isoform, with some kits
having only 44% of the response to the Ile325 variant compared to the Thr325 variant
(63). Therefore, conclusions made from studies in the past, which used these ELISAs to
measure plasma TAFI antigen levels, should be re-evaluated (19, 45-46, 63-66).
Overall, there seems to be a clear relationship between increased TAFI levels and
increased risk of venous thrombosis (50), recurrent venous thrombosis (51), and ischemic
stroke (52, 53, 61). However, the data from studies pertaining to CHD have resulted in
more inconsistent results (58, 59). A possible explanation for the differences in the
uniformity of the results from the CHD studies in comparison to the venous thrombosis
and ischemic stroke studies could be due to the differences in the structure of the
vasculature in which the clot is formed. For example, veins are large blood vessels, which
carry deoxygenated blood from the extremities back to the heart and lungs under lowpressure conditions (67). In contrast to the arteries, which carry oxygenated blood from
the heart to the extremities under high-pressure conditions (67).
Furthermore, the characteristics of the clots that form within each area are also
markedly different. In large arteries such as the coronary and carotid arteries, thrombi
form usually because of rupture of atherosclerotic plaque and are typically platelet-rich
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and fibrin-poor. Alternatively, in the venous system where atherosclerosis does not occur
and thrombi most commonly form due to stasis, red blood cell- and fibrin-rich clots tend
to form on undamaged endothelial walls (67). Hence, due to the differences in the
environment of the vasculature, as well as the components and the structure of the actual
clots in each environment, the relationship between TAFI and risk of developing
atherothrombotic disease becomes quite complex.
Although the role of TAFI in regulating fibrinolysis has been extensively
documented, proving its status as a risk factor for atherothrombotic disease has proven
difficult due to the results of several conflicting studies. In addition, even though the
relationship between elevated TAFI levels and risk of venous thrombosis and ischemic
stroke has been more direct, the mechanism by which elevated TAFI levels contributes to
venous thrombosis and ischemic stroke are still unknown. However, it is postulated that
increased TAFIa levels results in a decrease in fibrinolysis, which results in a clot that is
less likely to be lysed. Ultimately, while variation in plasma TAFI concentrations and
functional TAFI levels due to genetic and non-genetic factors appears to correlate with
vascular risk, more studies are required in order to clarify the role TAFI plays in the
development of atherothrombotic disease.

1.5 TAFI and the Regulation of Inflammation

Although the primary function of TAFI was originally demonstrated to be
inhibition of fibrinolysis through cleavage of carboxyl terminal lysine and arginine

	
  

24

residues from partially-degraded fibrin (41), many studies in the years following its
discovery have uncovered evidence that TAFI also plays a role in the modulation of
inflammation and the acute phase response. CPB2 mRNA levels and TAFI protein levels
were first shown to be elevated in mice following treatment with lipopolysaccharide
(LPS) (68). LPS is a major component of the cell membrane of gram-negative bacteria,
and can induce an inflammatory response by activating the complement pathway (69).
Besides fibrin, TAFIa has also been shown to be able to cleave bradykinin (70),
the complement anaphylatoxins, C3a and C5a (71), thrombin cleaved osteopontin, OPN
(72), and plasmin cleaved chemerin (73). TAFIa cleavage of bradykinin, C3a and C5a,
and thrombin cleaved OPN all result in inactivation of these pro-inflammatory mediators.
In contrast, TAFIa cleavage of chemerin results in an increased activity of this antiinflammatory mediator. Thus, the effect that TAFIa has shown to possess towards a
diverse array of inflammatory related substrates demonstrates TAFI’s role as an antiinflammatory mediator of the inflammatory response.
In assessing the role that established acute phase mediators had on CPB2 gene
expression, it was uncovered that treatment of HepG2 cells with IL-1β and IL-6 in
combination resulted in a 60% decrease in CPB2 mRNA abundance (16). However, no
effect was observed on CPB2 promoter activity. Furthermore, treatment of HepG2 cells
with a synthetic glucocorticoid, dexamethasone resulted in a 2-fold increase in CPB2
mRNA abundance. Further analysis led to the discovery of a glucocorticoid responsive
element (GRE), at position -92 to -78 within the human CPB2 promoter. Glucocorticoids
are hormones capable of down-regulating the acute phase response (APR) of the immune
system (74). Glucocorticoids can reduce the APR by inhibiting the expression of many
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pro-inflammatory cytokines, such as IL-1β, IL-6, and Tumor Necrosis Factor alpha
(TNFα). Furthermore, they can also reduce the activation of the pro-inflammatory
transcription factor NFκB by inducing the transcription of the NFκB inhibitor, IκB (74).
Thus, glucocorticoids can increase plasma TAFI concentration levels during the APR of
an inflammatory episode by reducing the expression of IL-1β, IL-6, and TNFα, which are
known to down-regulate CPB2 mRNA abundance.
The ability of TAFI to regulate inflammation within a hyper-inflammatory system
was studied by Asai and coworkers (69). With the knowledge that LPS treatment of mice
causes an up-regulation of CPB2 mRNA and TAFI protein levels, Asai and coworkers
(64), created TAFI deficient mice to assess TAFI’s role in a hyper-inflammatory state.
Mice were treated with cobra venom factor (CVF), which is known to activate the
complement cascade of the immune system. Surprisingly, there was no difference in
survival between TAFI deficient, heterozygous, or wild-type mice. However, when the
mice were pretreated with a sub-lethal dose of LPS prior to CVF treatment, 60% of TAFI
deficient mice died, compared to no death amongst the heterozygous or wild-type mice.
During an inflammatory response, complement activation leads to an increase in plasma
C5a, and LPS can induce the up-regulation of the C5aR. TAFIa has been previously
shown to be able to cleave C5a, and thus down regulate its pro-inflammatory effects.
TAFI deficient mice could not overcome the hyper inflammatory state induced by the
presence of excessive C5a, and thus mortality resulted. This study effectively
demonstrated the important role TAFI plays in inflammation in mice.
Studies in humans have provided contradictory results in comparison to results
obtained using mouse models. In a study conducted by Watanabe and coworkers (75), 36
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patients with disseminated intravascular coagulation (DIC) sepsis induced multiple organ
dysfunction syndrome (MODS), were found to have significantly lower TAFI antigen
and functional TAFIa levels in comparison to healthy controls. The results obtained from
this clinical study were further supported by a later study conducted by Zeerleder and
coworkers (76), who also investigated the association between TAFI antigen levels and
TAFIa activity in patients with severe sepsis. This study also reported significantly
decreased levels of TAFI and TAFIa in patients with severe sepsis, in comparison to
healthy controls.
A possible explanation for the discrepancy in TAFI levels between the two
species during an inflammatory episode came from a study conducted by Garand and
coworkers (77). In this study, they investigated the effect of another known acute phase
mediator TNFα and its effect on the expression of CPB2 in an inflammatory system.
Treatment of primary mouse hepatocytes with TNFα for 12-48 hours resulted in a twofold increase of CPB2 mRNA, a 2.7 fold increase in TAFI protein levels after 48 hours of
treatment with TNFα, and an increase in mouse CPB2 promoter activity by 1.5 fold.
Further analysis of the 5’ flanking region resulted in the discovery of a NFκB site within
the mouse promoter region that is not conserved in humans. Hence, in mice undergoing
an inflammatory response, activation of TNFα results in the translocation of the NFκB
transcription factor to the nucleus where it binds CPB2, and up-regulates its expression.
Overall, the precise role of TAFI in inflammation is still emerging. The ability of
TAFI to modulate the inflammatory response through inactivation of various proinflammatory cytokines and activation of anti-inflammatory cytokines demonstrates the
diverse mechanisms by which TAFI can affect the APR. Also, glucocorticoid
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enhancement of plasma TAFI concentrations during an inflammatory state suggests that
TAFI is required during a host’s immune system attack in order to reduce the likelihood
of developing sepsis (16). Sepsis is a state characterized by extreme stimulation of a
host’s immune system, and often is accompanied by the induction of a pro-coagulant
state in the host (76). Thus, TAFI serves as an important molecular link between the
coagulation cascade and the inflammatory system.

1.6 Platelet Pool of TAFI

Mosnier and coworkers (78) discovered a second pool of TAFI in the alpha granules
of platelets. CPB2 mRNA was detected within the well-characterized Dami
megakaryocytic cell line. The detection of CPB2 mRNA within this cell line suggests that
these cells are capable of producing their own endogenous TAFI source in contrast to
uptake of TAFI via endocytosis from the cell’s surroundings. Platelet TAFI was reported
to be smaller (~ 50 kDa) than plasma TAFI (~60 kDa), which was due to differential
glycosylation patterns. Removal of the glycosaminoglycans from both forms of TAFI
resulted in the expected migration of hypo-glycosylated TAFI at a MW of ~ 47 kDa on
SDS-PAGE (78). Platelet TAFI is similar functionally to plasma TAFI in that it is
effectively activated by thrombin in complex with thrombomodulin, and is unstable at
37°C (78). Activated platelets can release platelet TAFI to the site of injury, which can
also contribute to the antifibrinolytic effect of TAFI (78).
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In a latter study conducted by Schadinger and coworkers (79), however, it was found
that there is no difference in the electrophoretic mobility of platelet-derived TAFI in
comparison to plasma-derived TAFI. In this study, both sources of TAFI were found to
migrate on SDS-PAGE at approximately 58 kDa, thus they are not as drastically different
in size as was formerly reported (78). This study was also the first to show that plateletderived TAFI could function independently of plasma-derived TAFI to attenuate the lysis
of a platelet-rich thrombus (79). Platelet-rich thrombi are characteristically more resilient
to fibrinolysis than clots consisting of fibrin only (80). Thus, the secretion of TAFI from
the alpha granules of platelets during a thrombotic event advocates for a fibrinolytic
regulatory role of platelet derived TAFI independent of plasma derived TAFI. One such
role might be that platelet-derived TAFI acts from within the thrombus to prevent the
breakdown of the clot, while plasma-derived TAFI performs its antifibrinolytic functions
from the exterior of the clot (79). Thus, it is evident that activation of platelet-derived
TAFI at a site of vessel injury could have a substantial effect on the fibrinolytic cascade.

1.7 Extra-Hepatic TAFI

The plasma pool of TAFI arising from expression of CPB2 in the liver contributes the
majority of the TAFI circulating within the vasculature. In addition to the discovery of a
second pool of TAFI located within the alpha granules of platelets, further investigation
of TAFI within other tissues led to the finding of CPB2 mRNA within adipose tissue
(81), as well as human umbilical vein endothelial cells (HUVECs) (81) and human

	
  

29

peripheral blood mononuclear cells (PBMNC) using RT-PCR. However, no associated
TAFI protein was identified in these studies.
Since these initial discoveries, our laboratory has addressed the question of other
extra-hepatic TAFI sites in a more systematic and rigorous fashion. A study by Lin and
coworkers (82) led to the discovery of CPB2 mRNA within the leukemic monocyte cell
line THP-1 and re-confirmed the expression of CPB2 mRNA within PBMNCs. In
addition, low TAFI protein levels were also identified from the medium of THP-1 cells
differentiated into macrophages using a highly sensitive assay for TAFIa detection (82).
Furthermore, CPB2 mRNA expression was also re-confirmed in Dami cells, which is a
well-characterized megakaryocytic cell line (82).
Next, the researchers were interested in the association between stage of
differentiation and the level of CPB2 mRNA levels. Dami cells were treated with Phorbol
Myristate Acetate (PMA), which caused the cells to differentiate further along their
megakaryocytic cell lineage. CPB2 mRNA levels detected in Dami cells after
differentiation were found to be 4.5 fold higher than in un-differentiated Dami cells.
Hence, stage of differentiation was found to be an important factor in determining CPB2
mRNA abundance levels in these cells (82). Moreover, low TAFI protein levels were also
identified in the medium of differentiated Dami cells by western blot analysis. By using a
highly quantitative TAFIa assay, it was shown that the concentration of TAFI within the
medium of differentiated Dami cells is about one seventh the concentration of TAFI
within the medium of HepG2 cells. (82).
The discovery of CPB2 mRNA within the THP-1 monocytic cell line and PBMNC is
very intriguing because monocytes and macrophages are very important cells with
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respect to the inflammatory response. Upon initiation of an immune response, circulating
monocytes enter an infected tissue, where they differentiate into macrophages.
Macrophages can engulf pathogens, cellular debris, and can support an inflammatory
response. TAFIa has been previously shown to be able to cleave pro-inflammatory
cytokines, such as C3a and C5a of the complement system to inactivate them (71, 72),
which further supports the idea that TAFI has a role in the modulation of the
inflammatory response. The extra-hepatic pool of TAFI within monocytes and
macrophages suggests that TAFI may have other functions besides its ability to attenuate
fibrinolysis including, but not limited to, effects on inflammation.

1.8 Discovery of TAFI in the Brain and Alternative Splicing of TAFI

In a study by Matsumoto and coworkers (83), a novel alternatively-spliced form
of TAFI was discovered. Through northern blot analysis of RNA from seven different
tissues, the expression of this form of TAFI was determined to be brain (hippocampus)specific, and thus it was named Human Brain Carboxypeptidase B (HBCPB). In a later
study by the same group, they were able to detect HBCPB in human serum and
cerebrospinal fluid via western blot analysis (84).
From molecular sequence analysis, they discovered that HBCPB was highly related to
CPB2, which is synthesized in the liver (83). However, HBCPB was found to have two
major sequence differences with respect to CPB2. The first major difference in HBCPB is
the deletion of exon 7, which results in a deletion of 37 amino acids within the region
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spanning amino acids 198-234 of the mature protein. The second major structural
difference in HBCPB is due to a partial deletion in exon 11 of 52 base pairs between
nucleotides 1190-1241, which results in a deletion of 18 amino acids, and an addition of a
novel 14 amino acid residue carboxyl terminus. The exon 7 deletion results in an inframe deletion. However, the partial deletion in exon 11 results in an out of frame
deletion, and the use of new stop codon for translation. Outside of these changes, the
nucleotide sequences were identical between liver and brain transcripts, suggesting that
they arose from alternative splicing of the same primary transcript.
HBCPB was identified as a pre-pro-peptide of 40 kDa that is expressed in a
variety of healthy, human brain structures based on immunohistochemical analysis (85).
By using a novel anti-C14 antibody, which specifically recognizes the unique C-terminus
of HBCPB, they were able to show that HBCPB is expressed to a greater extent within
the hippocampus, amygdala, basal nucleus of Meynert, lateral geniculate body, and large
pyramidal neurons of the cerebral neo-cortex (85). In comparison to brain tissues from
patients with Alzheimer’s disease, a large reduction in HBCPB was most striking within
the hippocampus and amygdala, which are two structures that are known to be affected
by Alzheimer’s disease (85).
In vitro proteolytic analysis of HBCPB determined that the active form of
HBCPB, which is 30 kDa, could cleave β-amyloid precursor protein (β-APP) and its
derivative, Aβ1-42, into 10 to 12 kDa cleavage products (83, 86). Impaired processing of
β-APP results in amyloid plaque formation and aggregation within the brain (87).
Increased plaque formation interrupts signal transduction pathways between healthy
neurons, and can cause neuronal death over time. Neuronal death following increases in
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plaque formation within the brain is a well-known characteristic in the pathology of
Alzheimer’s disease. Alzheimer’s disease is a neurodegenerative disorder of the brain,
which eventually results in dementia due to the progressive death of neurons over time
(87). Thus, the discovery of a novel protease which can cleave β-APP into a nonamyloidogenic variant may prove significant for the development of a treatment for
patients with Alzheimer’s disease.
A subsequent study by Cagliani and coworkers (88) investigated the regions
between exon 6 and exon 7 (region one), and exon 9 to the 3’-UTR (region two) of CPB2
to re-confirm the alternative splicing events previously documented by Matsumoto and
coworkers (83). First, they assessed the rate of nucleotide diversity between Europeans
(United Kingdom), East Asians and Yorubans (West Africans) for region one and region
two. It was found that there is a high degree of nucleotide diversity in region one across
all three ethnic groups, which is indicative of balancing selection. Region two showed no
significant difference in any ethnic group, and was concluded to be functioning under
neutral evolution.
In addition, they were also able to demonstrate that the SNP located within exon 6
(+505A/G), which has previously been shown not to affect TAFI stability or enzyme
activity (18), was preferentially associated with skipping of exon 7. Although the
function of the variant lacking the residues encoded by exon 7 is currently unknown, it
was suggested by the authors that balancing selection helps to maintain the alternatively
spliced product within the population due to heterozygote advantage. The authors were
also able to detect the wild-type and exon 7-lacking mRNA in HepG2 cells and in two
different liver specimens by RT-PCR. However, amplicons indicative of the exon 11
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alternative splicing event were not observed. The authors suggested that the reason why
they were unable to detect the exon 11 alternative splicing event is either because of its
brain tissue specificity or because its occurrence in the liver arises under different
parameters then the ones they had investigated.
A study conducted by Lin and coworkers (89) set out to confirm these previous
reports of alternatively spliced CPB2 mRNA in the brain and the liver, as well as to
investigate the extent of splicing that occurs within tissues and cell types that are central
to vascular biology. In addition, the ability of TAFI protein translated from the
alternatively spliced CPB2 mRNA to function like TAFIa was also assessed. RNA from
various human tissue samples was extracted and RT-PCR experiments were performed
with various TAFI primer sets designed to identify the various alternatively spliced CPB2
mRNA variants. RT-PCR analysis revealed that alternatively spliced TAFI variants were
found in all tissues tested, which included brain (cerebellum and cortex), testis, and liver.
One of the novel and interesting findings from this study was the presence of full length
CPB2 cDNA within the cerebellum and the cortex. This was the first report of full length
CPB2 cDNA within the brain. mRNA missing exon 7 was also found in the cerebellum,
liver and testis, but not in the cortex. mRNA containing alternatively spliced exon 11 was
also identified in the cortex, cerebellum and testis, but not in the liver. The presence of
exon 7-lacking mRNA within the liver and the absence of exon 11 alternative splicing
from the liver were both in accordance with the previous report by Cagliani and
coworkers (88).
Lin and coworkers (89) also used the same TAFI primer sets to analyze RNA
extracted from platelets, HepG2 cells, and SH-SY5Y (neuroblastoma) cells. In SH-
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SY5Y cells, the exon 7-lacking and exon 11 alternatively spliced variants were actually
found to be the major transcripts present. As with the HepG2 cells, three cDNA species
were amplified with a primer set flanking exon 7: two of the bands were identified as full
length and exon 7-lacking CPB2 cDNA while the third represented a novel alternatively
spliced variant lacking exon 7 and exon 8. This species was also detected in HepG2 cells,
cerebellum, and testis. The skipping of both exon 7 and exon 8 results in a frameshift and
premature termination 70 base pairs into exon 9. Thus, like HBCPB this variant has a
novel carboxyl-terminus although it is 23 amino acids in length in comparison to the 14
amino acid unique C-terminus of HBCPB and is missing even more of the amino acid
residues present in full-length TAFI (89).
In a prior study by Lin and coworkers (82), while trying to detect full length
CPB2 mRNA within extra hepatic sites using RT-PCR, they noticed recurring bands of
smaller sizes along with their expected full-length amplicons. With the new knowledge of
alternative splicing events of CPB2 mRNA occurring within the brain and liver, they set
out to determine if those bands they had seen previously in the megakaryocyte cell line
(Dami) and monocytoid cell line (THP-1) likewise represented alternative splicing
events. From the RT-PCR results, exon 7 skipping was also detected in differentiated
Dami cells and THP-1 derived macrophages. In addition, exon 7 and 8 skipping was
detectable in differentiated Dami cells, but to a lesser degree (89).
Lin and coworkers (89) also assessed the ability of alternatively spliced TAFI to
encode a functional TAFI protein. Expression plasmids containing the full length (wt)
and alternatively spliced variants (known as Δ7, Δ11, and Δ7+11) were constructed and
stably transfected into the Baby Hamster Kidney (BHK) cell line, which does not
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endogenously express TAFI. From western blot analysis using a polyclonal anti-TAFI
antibody, full-length TAFI (60 kDa) was detected in conditioned medium of cells
transfected with full-length TAFI expression plasmid while no immuno-reactive bands
were detected in medium harvested from cells transfected with any of the other
expression plasmids. Interestingly, however, within lysates immuno-reactive bands
between of the appropriate sizes (40-48 kDa) in size were detected for all the expression
plasmids. These likely represent immature, incompletely glycosylated forms of the
recombinant proteins present in the endoplasmic reticulum (ER). Only the cells
transfected with the full-length TAFI expression plasmid, however, showed the mature
and fully glycosylated 60 kDa form within the lysates.
Western blot analysis showed that the full-length TAFI present in either the
conditioned medium or the lysates could be activated by thrombin-thrombomodulin. In
parallel experiments performed in transfected HepG2 cells, only full-length TAFI was
detected in the medium. TAFIa activity was readily detected in thrombinthrombomodulin-treated medium or lysates from BHK cells transfected with the fulllength TAFI expression plasmid. However, no TAFIa activity was detected in medium or
lysates of BHK cells transfected with alternatively-spliced TAFI variants.
Thus, the authors concluded that alternatively spliced TAFI is not secreted from
the cell, and cannot be activated by thrombin-thrombomodulin. It is possible that the
missing amino acid residues prevent the protein from being properly folded and thus
released from the endoplasmic reticulum into the secretory pathway. The findings suggest
the possibility of an intracellular role for TAFI variants arising from alternative splicing
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or that alternative splicing performs a regulatory function to limit the expression and
secretion of TAFI.

1.9 Rationale, Hypothesis, and Thesis Objectives

Within the human population, there is considerable variation in the plasma TAFI
antigen level, which ranges anywhere from 73 to 275 nm (41, 42). Higher levels of
plasma TAFI or TAFIa have been associated with an increased risk for various vascular
pathological disorders including venous thrombosis (50), recurrent venous
thromboembolism (51), ischemic stroke (52, 53, 55) and CAD (58). Genetic studies (46,
49) have shown that only 15-25% of this variation is attributable to SNPs. Thus, the
majority of the factors that contribute to the regulation of CPB2 gene expression remain
largely unknown. Evidence of extra-hepatic TAFI expression, and alternative splicing of
CPB2 mRNA within these sites, suggests that TAFI may have other functions in addition
to its role in fibrinolysis.
The hypothesis of this study is that the extent of alternative splicing of CPB2 mRNA
within a cell type is regulated in a cell-specific manner, and that the alternatively spliced
CPB2 mRNA encodes TAFI variants with distinct functions.
The objectives of this research project are:
1.)

To determine quantitatively the extent of alternative splicing within various
vascular and inflammatory cell types, and whether a minigene approach can be
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used to recapitulate the alternative splicing pattern previously documented in
literature for further study.
2.)

To identify proteins within HepG2 cells that are translated from alternatively
spliced TAFI variants.
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Chapter 2: Materials and Methods

2.1 MiniGene1 and Minigene2 Rationale

To study the extent of alternative splicing of CPB2 in various vascular and
immune cell types, two minigene constructs were designed (Figure 2.1.A and Figure 2.2).
Minigene1 was constructed to include two constitutively expressed exons (exon 6 and
exon 9 of CPB2) that surround two alternatively spliced exons (exon 7 and exon 8 of
CPB2) (Figure 2.1.A). Minigene2 was constructed to include one constitutively
expressed exon (exon 10) and one alternatively spliced exon (exon 11) (Figure 2.2).
Minigene1 can be alternatively spliced to produce three variants (Figure 2.3): Full length
Minigene1, which contains exons 6, 7, 8, and 9 of CPB2 (Figure 2.3.A); Δ7 Minigene1,
which contains exons 6, 8, and 9 of CPB2 (Figure 2.3.B), and Δ7+8 Minigene1, which
contains exons 6 and 9 of CPB2 (Figure 2.3.C). Minigene2 can be alternatively spliced to
produce two variants (Figure 2.4): Full length Minigene2, which contains exons 10, and
the full length version of exon 11 of CPB2 (Figure 2.4.A); and Δ11 Minigene2, which
contains exons 10, and the alternatively spliced version of exon 11 of CPB2 (Figure
2.4.B).
On either end of the CPB2 DNA fragments, two irrelevant short sequences of
EGFP were added to distinguish between minigene CPB2 gene expression and
endogenous CPB2 gene expression (Figure 2.1.A and Figure 2.2). To ensure that each
minigene undergoes splicing, approximately 300 bp of intronic region was included
before and after each alternatively spliced exon of interest. 300 bp of intronic region was
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chosen because the primary regulatory elements for alternative splicing events are usually
located within 200-300 bp upstream and downstream of the exon of interest (97). Both
minigenes were constructed in a plasmid that contains a strong constitutive promoter
(from cytomegalovirus) to ensure that transcription from the minigenes are initiated
without the need for an inducer molecule.
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A.

B.

Figure 2.1. Plasmid Construction of Minigene1.
Two versions of minigene1 were constructed, which differ only in the promoter
that drives their expression in their respective plasmids. Version 1 of Minigene1 was
constructed with a pCMV promoter in the pcDNA4/myc-his-A plasmid, and was the
primary minigene1 used in the following experiments throughout this thesis. Version 2 of
Minigene1 which contains a pTET promoter in the pcDNA4/myc-his-B plasmid, was
produced for future work. The location and type of restriction enzymes used to construct
the minigenes are indicated by the black arrows. In addition, exons are indicated by the
boxes, and the introns are indicated by the broken dashed lines. Also, the sizes of the
respective exonic and intronic regions included in the constructs are also indicated.
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Figure 2.2. Plasmid Construction of Minigene2
Minigene2 was constructed with a pCMV promoter in the pcDNA4/myc-his-A
plasmid, and was the primary minigene2 used in the following experiments throughout
this thesis. The location and type of restriction enzymes used to construct the minigenes
are indicated by the black arrows. In addition, exons are indicated by the boxes, and the
introns are indicated by the broken dashed lines. Also, the sizes of the respective exonic
and intronic regions included in the constructs are also indicated.
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A.

B.

C.

Figure 2.3. Splice Variants of Minigene1.
The following are schematic images indicating the resulting transcripts that could
arise from alternative splicing of the pCMV-minigene1-4A plasmid. A. Full Length (FL)
Minigene1, which contains all exons. B.) Δ7 Minigene1, which is representative of exon
7 skipping only. C. Δ7+8 Minigene1, which is representative of both exon 7 and exon 8
skipping. Also shown is the polyA tail that would be present on the following transcripts.
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A.

B.

Figure 2.4. Splice Variants of Minigene2
The following are schematic images indicating the resulting transcripts that could
arise from alternative splicing of the pCMV-minigene2-4A plasmid. A. Full Length (FL)
Minigene2, which contains exon 10 and the full length version of exon 11. B.) Δ11
Minigene2, which contains exon 10 and the alternatively spliced version of exon 11. Also
shown is the polyA tail that would be present on the following transcripts.
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2.2.A Minigene1 Construction

Primer sets were designed to amplify two irrelevant sequences within Enhanced
Green Fluorescent Protein (EGFP), using pEGFP-C3 as a template to perform PCR. In
addition, primer sets were designed to amplify sequences surrounding each exon of
CPB2, as well as intronic sequences approximately 300 base pairs upstream and
downstream of each exon. Genomic DNA (gDNA) was extracted from THP-1
monocytes, using QIAamp DNA Blood Midi kit (Qiagen), and used as a template to
perform PCR for the CPB2 sequences. See Table 2.1 for primer sequences, engineered
restriction sites, expected amplicon sizes, and annealing temperatures. PCR amplification
of the desired sequence was carried out with the appropriate primer pairs, using Taq
DNA Polymerase (GoTaq Green Master Mix - Promega). In a 96-well optical plate
(BioRad), 12.5 µL of 2× GoTaq Green Master Mix (final concentration 1×), was added to
150 ng of gDNA template and 2.5 µL of each forward and reverse primers (final
concentration 1 µM). Thermocycling conditions were carried out as follows:
predenaturation at 95°C for 2 minutes, 40 cycles of denaturation at 95°C for 30 seconds,
annealing at a primer pair-specific temperature (See Table 2.1) for 30 seconds, extension
at 72°C for 2 minutes, and a final extension at 72°C for 5 minutes.
PCR products were resolved on a 1% agarose gel to separate the amplified
products. Bands of the correct size were excised from the gel and isolated using a Gene
Clean III kit (MP Biomedicals). The PCR products were digested with the appropriate
restriction enzymes corresponding to the flanking engineered cut sites for 1 hour at 37°C.
In parallel, the pBluescript SK II + vector (Stratagene) was digested with EcoRV for 1
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Table 2.1. Primer Sequences Used to Construct Minigene1
Primer
Name

Primer Sequence (5’ à 3’)

Expected
Size

Restriction
Site

Annealing
Temperature
( °C)

5’ EGFP – 5’
Primer

ATG GAT CCG CAA GGG CGA
GGA GCT GTT CAC CGG G

160 bps

BamHI

69°C

5’ EGFP – 3’
Primer

ATG AAT TCG GCC AGG GCA
CGG GCA GCT TGC CGG TG

Region 6 –
5’ Primer

ATG AAT TCG TTT CTG GAA
AAG AAC AAG CAG CC

Region 6 –
3’ Primer

ATC TGC AGC ATA CAG TTT
GTC TTA TAT ATG GC

Region 7 –
5’ Primer

Region 8 –
5’ Primer

ATC TGC AGC TGC CTT CAT
TAA CTA GGA ATA CTG GAC
CAC GTG TAA GGC
ATG ATA TCA TGC ATA CTG
AAA TAT TTA TTG ATG AAG
TGA TAT GGT ACC
ATG ATA TCC GGA TAG CAA
TAG GGA CCG TGC

Region 8 –
3’ Primer

ATG CGG CCG CGT CAA CAC
AGC AAG ACT CTG

Region 9 –
5’ Primer

3’ EGFP – 5’
Primer

ATG CGG CCG CGG GAC
AGG GGG AGA AGT GTT
GGA AGG CAG CC
ATC TCG AGC AGT TCC TCA
TGG TCT TTG CTT TTA CTT
CGT GTA TAG
ATC TCG AGC CTG ACC TAC
GGC GTG CAG TGC TTC AG

3’ EGFP – 3’
Primer

ATT CTA GAC GCC CTC GAA
CTT CAC CTC GGC GCG G

Region 7 –
3’ Primer

Region 9 –
3’ Primer

	
  

EcoRI
630 bps

EcoRI

60°C

PstI
660 bps

PstI

65°C

EcoRV
680 bps

EcoRV

62°C

NotI
800 bps

NotI

72°C

XhoI
168 bps

XhoI

70°C

XbaI
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hour at 37°C. All digests were subsequently resolved on a 1% agarose gel. Correctly
digested fragments were excised from the agarose gel, and isolated using Gene Clean III
kit (MP Biomedicals). The ligation reaction was performed using 6.5 µL PCR product
“insert,” 0.5 µL of pBluescript “vector,” 1 µL of T4 DNA Ligase (Invitrogen), and 2 µL
of T4 DNA Ligase Reaction Buffer (Invitrogen) overnight at 16°C within a minithermocycler (MJ Research PTC-150 MiniCycler).
The DNA in the ligations was then ethanol-precipitated and dissolved in MilliQH2O before introduction into electrocompetent MAX Efficiency DH5α competent cells
(Invitrogen) via electroporation. Cells were allowed to recover for 40 minutes in Luria
broth (LB) at 37°C before being plated onto LB-ampicillin (100 µg/mL) (Fisher) agar
plates with 1 mg of 5-bromo-4-chloro-3indolyl-beta-D-galactopyranoside (Xgal)
(Bioshop), and 2 mg of isopropyl thiogalactoside (IPTG) (Sigma) for colony color
selection. After overnight growth, colonies were picked and grown overnight in LB broth
with 100 µg/mL of ampicillin (Fisher) for selection. The next day, plasmid DNA was
isolated and digested with the appropriate restriction enzymes. Samples that yielded the
correct band sizes were sent for sequencing (Robarts Research Institute DNA Sequencing
Facility). DNA from clones of the correct sequences was prepared using a Plasmid Plus
Midi Prep kit (Qiagen), and digested with the appropriate restriction enzymes to re-verify
their identity.
This general cloning method was used to produce each individual fragment for the
minigene within the pBluescript SK II + vector. Once all clones had been successfully
constructed within pBluescript SK II +, they were sequentially inserted into the
pcDNA4/myc-his-A vector, which has a strong cytomegalovirus promoter (pCMV). This
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was accomplished via a series of three part and two part ligations. To insert 5’-EGFP and
region-6 into pcDNA4/myc-his-A, a three-part ligation was employed. pcDNA4/myc-hisA (0.5 µg) was digested with BamHI and PstI, 5 µg of 5’EGFP-pBlue was digested with
BamHI and EcoRI, and 2 µg of region 6-pBlue were digested with EcoRI and PstI for 1
hour at 37°C. DNA fragments were each resolved on agarose gels and isolated as
described above in 8 µL of TE Buffer (10 mM Tris, 1 mM EDTA, pH 8). The ligation
reaction was performed with: 5 µL of 5’EGFP, 1.5 µL of region 6, 0.5 µL of
pcDNA4/myc-his-A, 1 µL of T4 DNA Ligase (Invitrogen), and 2 µL of T4 DNA Ligase
Reaction Buffer (Invitrogen) overnight at 16°C within a mini-thermocycler (MJ Research
PTC-150 MiniCycler). Ligation reactions were precipitated and transformed into
electrocompetent E. coli as described above and correctly assembled clones identified by
restriction digestion and DNA sequencing as described above.
The rest of the inserts for mingene1 were introduced into this first intermediate
construct in two part ligations, using similar approaches. The final minigene construct in
pcDNA4/myc-his-A was subjected to various double digestion reactions to ensure all of
the inserts were present as well as complete sequencing of the entire insert to ensure the
fidelity of the sequence.
In addition, a second version of the minigene1 construct was created within a
modified pcDNA4/myc-his-B vector with an inducible pTET promoter. The complete
minigene1-4A plasmid was digested with BamHI and XbaI, and 0.5 µg of pTETpcDNA4/myc-his-B was also digested with BamHI and XbaI. The ligation reaction was
performed using 6.5 µL insert, 0.5 µL of vector, 1 µL of T4 DNA Ligase (Invitrogen) and
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2 µL of T4 DNA Ligase Reaction Buffer (Invitrogen) overnight at 16°C. Correctly
assembled clones were isolated and verified as described above.

2.2.B. MiniGene2 Construction

Primer sets were designed to amplify sequences surrounding exon ten of CPB2
and 300 base pairs of intronic sequence downstream of exon 10, exon 11 of CPB2, and
300 base pairs of intronic sequence upstream of exon 11 in CPB2. gDNA was extracted
from THP-1 monocytes using QIAamp DNA Blood Midi kit (Qiagen) and used as a
template to perform PCR for the CPB2 sequences. See Table 2.2 for primer sequences,
engineered restriction sites, expected amplicon sizes and annealing temperatures. PCR
amplification of the desired sequence was carried out with the appropriate primer pairs
using Q5 High-Fidelity DNA Polymerase (NEB).
Reactions were assembled in a 0.6-ml Eppendorf tube (Sarstedt) and contained 10
µL of 5× Q5 Reaction Buffer (final concentration 1×), 1 µL of dNTPs (final
concentration 0.2 mM of each), 10 µL of 5× Q5 High GC Enhancer (final concentration
1×), 250 ng of gDNA template, 0.5 µL of Q5 High – Fidelity DNA Polymerase (final
concentration 0.02 U/µL) and 2.5 µL of the forward and reverse primers (final
concentration 0.5 µM). Thermocycling conditions were carried out as follows for both
region-10 and region-11: predenaturation at 98°C for 30 seconds, 35 cycles of
denaturation at 98°C for 10 seconds, annealing at 57°C for 30 seconds, and extension at
72°C for 20 seconds, and a final extension at 72°C for 5 minutes.
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Table 2.2. Primer Sequences Used to Construct Minigene2

Primer Name

	
  

Primer Sequence (5’ à 3’)

Region 10 – 5’
Primer

ATG AAT TCT CTC TAG
TAG CCA GTG AAG C

Region 10 – 3’
Primer

ATC TGC AGG TCA CAA
GTT TTG TGT GTC

Region 11 – 5’
Primer

ATC TGC AGG TAG ACA
AAT GAG G

Region 11 – 3’
Primer

ATC TCG AGT TAA ACA
TTC CTA ATG ACA TGC C

Expected
Size

Restriction
Site

Annealing
Temperature
( °C)

564 bps

EcoRI

57°C

PstI
677 bps

PstI

57°C

XhoI
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PCR products were resolved on 1% agarose gels and isolated as described above
in Section 2.1.A. The isolated PCR products were digested with the appropriate flanking
engineered cut sites for 1 hour at 37°C. In addition, 0.5 µg of minigene1-4A was digested
with EcoRI and XhoI for 1 hour at 37°C to remove the CPB2 region within minigene14A, so that the plasmid retained only the two EGFP inserts at each end. The ligation
reaction was assembled containing 0.5 µL of EGFPminigene1-4A, 3.2 µL of region-10
digested PCR product, 3.2 µL of region-11 digested PCR product, 0.2 µL of T4 DNA
Ligase (Invitrogen), 2 µL of T4 DNA Ligase Reaction Buffer (Invitrogen), and 0.9 µL of
H2O. After transformation of electrocompetent E. coli, correctly assembled clones were
identified and verified as described above in Section 2.2.A.

2.2.C. Expression Plasmids for Full Length TAFI and Alternatively Spliced TAFI
Variants

See Figures 2.5 - 2.8 for a schematic diagram of all the Full length and alternatively
spliced TAFI variant expression plasmids constructed and used throughout this study.
Primer sets were designed to amplify sequences surrounding the full length TAFI
sequence, as well as each alternatively spliced TAFI variant. In addition, novel restriction
enzyme sites were designed at each end of the fragment for sticky ended insertion into
the plasmid of interest. Previous plasmids containing the sequences of interest in a pNUT
plasmid (89) were used as templates for each construct. See Table 2.3 for primer
sequences, engineered restriction cut sites, expected amplicon sizes, and annealing
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Figure 2.5. Plasmid Construction of Full Length TAFI Variants
Full length TAFI was cloned into three different expression plasmids: A. Full
Length TAFI + pCMV-pBluescript SK II +. B. Full Length TAFI + pTET-pcDNA4/mychis-B, and C. Full Length TAFI + pCMV-pcDNA4/myc-his-A. Version A. and Version
B. of the Full Length TAFI variants were intermediates synthesized during the production
of the final product, Version C. The Full Length TAFI + pCMV-pcDNA4/myc-his-A
version was the plasmid used for experiments throughout this thesis. The location and
type of restriction enzymes used to construct the Full Length TAFI variants are indicated
by the black arrows. Also, the sizes of the respective insert and plasmid regions included
in the constructs are also indicated. The plasmids that contain a myc 6x His tag are also
indicated.
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Figure 2.6. Plasmid Construction of Δ7 TAFI Variants
Δ7 TAFI was cloned into three different expression plasmids: A. Δ7 TAFI +
pCMV-pBluescript SK II +. B. Δ7 TAFI + pTET-pcDNA4/myc-his-B, and C. Δ7 TAFI +
pCMV-pcDNA4/myc-his-A. Version A. and Version B. of the Δ7 TAFI variants were
intermediates synthesized during the production of the final product, Version C. The Δ7
TAFI + pCMV-pcDNA4/myc-his-A version was the plasmid used for experiments
throughout this thesis. The location and type of restriction enzymes used to construct the
Δ7 TAFI variants are indicated by the black arrows. Also, the sizes of the respective
insert and plasmid regions included in the constructs are also indicated. The plasmids that
contain a myc 6x His tag are also indicated.
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Figure 2.7. Plasmid Construction of Δ11 TAFI Variants
Δ11 TAFI was cloned into three different expression plasmids: A. Δ11 TAFI +
pCMV-pBluescript SK II +. B. Δ11 TAFI + pTET-pcDNA4/myc-his-B, and C. Δ11
TAFI + pCMV-pcDNA4/myc-his-A. Version A. and Version B. of the Δ11 TAFI
variants were intermediates synthesized during the production of the final product,
Version C. The Δ11 TAFI + pCMV-pcDNA4/myc-his-A version was the plasmid used
for experiments throughout this thesis. The location and type of restriction enzymes used
to construct the Δ11 TAFI variants are indicated by the black arrows. Also, the sizes of
the respective insert and plasmid regions included in the constructs are also indicated.
The plasmids that contain a myc 6x His tag are also indicated.
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Figure 2.8. Plasmid Construction of Δ7+11 TAFI Variants
Δ7+11 TAFI was cloned into three different expression plasmids: A. Δ7+11 TAFI
+ pCMV-pBluescript SK II +. B. Δ7+11 TAFI + pTET-pcDNA4/myc-his-B, and C.
Δ7+11 TAFI + pCMV-pcDNA4/myc-his-A. Version A. and Version B. of the Δ7+11
TAFI variants were intermediates synthesized during the production of the final product,
Version C. The Δ7+11 TAFI + pCMV-pcDNA4/myc-his-A version was the plasmid used
for experiments throughout this thesis. The location and type of restriction enzymes used
to construct the Δ7+11 TAFI variants are indicated by the black arrows. Also, the sizes of
the respective insert and plasmid regions included in the constructs are also indicated.
The plasmids that contain a myc 6x His tag are also indicated.
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Table 2.3. Primer Sequences Used to Construct the Alternatively Spliced TAFI
Variants
Primer
Name

Primer Sequence
(5’ à 3’)

Expected Size

TAFI –
5’ Primer

AAA CTG CAG TTG
GGA TGA AGC TTT
GCA

FL = 1296 bps
Δ7 = 1185 bps
Δ11 = 1244 bps
Δ7+11 = 1133 bps

TAFI –
3’ Primer

GGG TCT AGA AAC
AAT CCT AAT GAC
AT

TAFI
MUT –
5’ Primer

ATG TTT CTA GAG
GGC CC(G)C GGT
TCG AAC AAA
AACT
AGT TTT TGT TCG
AAC CGG GGC CCT
CTA GAA ACAT

TAFI
MUT –
3’ Primer

	
  

Restriction
Site

PstI

Annealing
Temperature
( °C)
FL (Pfu) 60°C
Δ7 (Pfu) 60°C
Δ7+11 (Taq) 60°C

XbaI

G IS DELETED

67°C (all)
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temperatures. PCR amplification of full length TAFI and the Δ7 TAFI sequences were
carried out with the appropriate primer pair, using Pfu Turbo DNA Polymerase (Agilent).
The reaction contained 2.5 µL of 10× Cloned Pfu DNA Polymerase Reaction Buffer
(final concentration 1×), 0.2 µL of dNTPs (final concentration 0.2 mM of each), 50 ng of
plasmid template (full length TAFI-pNUT or Δ7 TAFI-pNUT), 0.5 µL of each forward
and reverse primer (final concentration 50 ng/uL) and 0.5 µL of Pfu Turbo DNA
Polymerase (2.5 U/µL). Thermocycling conditions were carried out as follows for both
full length TAFI and Δ7 TAFI: predenaturation at 95°C for 2 minutes, 30 cycles of
denaturation at 95°C for 30 seconds, annealing at 60°C for 30 seconds, and extension at
72°C for 1 minute for 30 cycles, and a final extension at 72°C for 10 minutes.
PCR products were resolved on and isolated from 1% agarose gel and then
digested with PstI and XbaI restriction enzymes for 1 hour at 37°C. In addition, 0.5 ug of
pBluescript SK II + was digested with PstI and XbaI for 1 hour at 37°C. The ligation
reaction was assembled from the gel-purified fragments: 6.5 µL of PCR amplified
digested product, 0.5 µL of digested pBluescript SK II + vector, 1 µL of T4 DNA Ligase
(Invitrogen), and 2 µL of T4 DNA Ligase Reaction Buffer (Invitrogen). Correctly
assembled clones were identified and verified as described above in Section 2.2.A.
PCR amplification of Δ7+11 TAFI sequence was carried out with the appropriate
primer pair using Taq Polymerase (GoTaq Green Master Mix Promega) in a reaction
containing 12.5 µL of 2× GoTaq Green Master Mix (final concentration 1×), 150 ng of
gDNA template, and 2.5 µL of each forward and reverse primers (final concentration 1
µM). Thermocycling conditions were carried out as follows: predenaturation at 95°C for
2 minutes, 40 cycles of denaturation at 95°C for 30 seconds, annealing at 60°C for 30
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seconds, and extension at 72°C for 2 minutes for 40 cycles, and final extension at 72°C
for 5 minutes. PCR products were inserted into pBluescript SK+ using PstI and XbaI sites
for the full length and Δ7 inserts described above.
To construct the Δ11 TAFI-pBlue plasmid, the full length segment was substituted
for the corresponding Δ7-containing segment in Δ7+11-pBlue using unique BglII and
SphI restriction sites that flank these segments.
Once all clones had been successfully constructed within pBluescript SK II +,
each cDNA segment was then inserted into a modified pcDNA4/myc-his-B vector with
an inducible pTET promoter (89). One microgram of each pBluescript SK II + plasmid
containing either FL TAFI, Δ7 TAFI, Δ11 TAFI, or Δ7+11 TAFI cDNA was digested
with PstI and XbaI to release the cDNA inserts, and 0.5 µg of pTET-pcDNA4/myc-his-B
was also digested with PstI and XbaI at 37°C for 1 hour. The fragments were isolated
from agarose gel slices and ligation reactions assembled using 6.5 µL insert, 0.5 µL of
vector, 1 µL of T4 DNA Ligase (Invitrogen), and 2 µL of T4 DNA Ligase Reaction
Buffer. Ligation conditions, bacterial transformation, and identification of correct clones
were performed as described above in Section 2.2.A.
Since the original primers for these constructs were designed for the
pcDNA4/myc-his-A plasmid, and the pcDNA4/myc-his-B plasmid has an extra
restriction cut site within its multiple cloning site that is not conserved in the
pcDNA4/myc-his-A plasmid; insertion of the TAFI inserts into pTET-pcDNA4/myc-hisB vector resulted in a frameshift that caused the sequence to be out of phase with the
myc-6× his tag within the pTET-pcDNA4/myc-his-B plasmid as confirmed by
sequencing analysis. Thus, mutagenesis of all the pTET-pcDNA4/myc-his-B constructs
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containing FL TAFI, Δ7 TAFI, Δ11 TAFI, and Δ7+11 TAFI, had to be performed. The
mutagenesis primers used for all constructs can be found in Table 2.3 and were designed
using Agilent software. Mutagenesis was carried out using a Quick-Change II-E SiteDirected Mutagenesis Kit (Agilent), which contains a PfuUltra High Fidelity DNA
Polymerase. In 96-well optical plates (BioRad), 5 µL of 10× Reaction Buffer (final
concentration 1×), 1 µL of dNTPs (final concentration 0.02 mM), were added to 50 ng of
DNA template and 5 µL of each forward and reverse primers (final concentration 25
ng/µL). Thermal cycling conditions used for all reactions were: predenaturation at 95°C
for 1 minute, 19 cycles of denaturation at 95°C for 50 seconds, annealing at 67°C for 50
seconds and extension at 68°C for 8 minutes, and then final extension at 68°C for 30
seconds. Following PCR, samples were digested with 1 µL of DpnI for 3 hours at 37°C to
digest the parental DNA. Following digestion, samples were precipitated with 3M
sodium acetate and 3 volumes of ethanol. Pellets were dissolved in MilliQ-H2O before
electroporation into electrocompetent MAX Efficiency DH5α competent cells
(Invitrogen). The presence of the correct mutations was verified by DNA sequence
analysis.
In addition, a third version of the full length and alternatively spliced constructs
was created within the pcDNA4/myc-his-A vector, which has a strong cytomegalovirus
promoter (pCMV). To insert each fragment into pcDNA4/myc-his-A, 1 µg of each inframe pTET-pcDNA4-myc-his-B plasmid containing either FL TAFI, Δ7 TAFI, Δ11
TAFI, or Δ7+11 TAFI was digested with PstI and XbaI and the inserts ligated into
pcDNA4/myc-his-A digested with the same enzymes. Transformation, plasmid isolation
and verification of clones as was described above in Section 2.2.A.
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2.3 Cell Culture

All cells were sustained in a humidified incubator at 37°C and 95% air, 5% CO2
atmosphere. HepG2 (human hepatocellular carcinoma) cells (American Type Culture
Collection (ATCC)) were cultured in 100 mm tissue culture plates in minimal essential
medium (MEM) (Gibco), supplemented with 10% fetal bovine serum (FBS) (ATCC),
and 1% antibiotic-antimycotic (10 units/mL penicillin G sodium, 10 ug/mL streptomycin
sulfate, and 25 ng/mL amphotericin B) (Gibco).
Baby Hamster Kidney (BHK) cells were cultured in 100 mm tissue culture plates in
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco), supplemented with 10%
newborn calf serum (NCS) (Gibco), and 1% antibiotic-antimycotic (Gibco).
Human Embryonic Kidney (Hek293) cells were cultured in 100 mm tissue culture
plates in minimal essential medium (MEM) (Gibco), supplemented with 5% fetal bovine
serum (FBS) (Gibco), and 1% antibiotic-antimycotic (Gibco).
SH-SY5Y (neuroblastoma cells) cells were generously provided by Dr. Siyaram
Pandey (Dept, of Chemistry & Biochemistry, University of Windsor). SH- SY5Y cells
were cultured in 100 mm tissue culture plates in Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco), supplemented with 10% fetal bovine serum (FBS) (Gibco), and 1%
antibiotic-antimycotic (Gibco).
THP-1 (human acute monocytic leukemia) cells were cultured in 100 mm tissue
culture plates with RPMI 1640 medium (Gibco), supplemented with 10% fetal bovine
serum (FBS) (Gibco), 1% antibiotic-antimycotic (Gibco), 1% Sodium Pyruvate (Gibco),
and 0.075mM of 2-mercaptoethanol (Sigma).
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To differentiate THP-1 cells into a macrophage-like phenotype, Phorbol Myristate
Acetate (PMA) (Sigma) was added to the cells at a final concentration of 0.1 µM, and the
cells incubated for 72 hours.

2.4 Transfection of Expression Plasmids for RT-PCR and qRT-PCR

2.4.A. Transfection of Minigene1-4A

HepG2 and Hek293 cells were transfected in 100 mm tissue culture plates, at
approximately 60% confluency, with 5 µg of minigene1-pcDNA4A with MegaTran 1.0
according to the manufacturer’s protocol.
SH-SY5Y cells were transfected in 100 mm tissue culture plates, at approximately
70% confluency, with 6 µg of minigene1-pcDNA4A, 18 µL of Lipofectamine 2000
(Invitrogen), 6 µL of Plus reagent in 1 mL of Opti-MEM, as per the manufacturer’s
protocol.
THP-1 cells were transfected in 60 mm tissue culture plates, at approximately 4
million cells/plate, with 8 µg of DNA, 18.6 µL of Lipofectamine 2000 (Invitrogen), 13.3
µL of Plus Reagent in 500 µL of Opti-MEM, as per the manufacturer’s protocol.
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2.4.B. Transfection of Minigene2-4A

HepG2, Hek293, and BHK cells were transfected in 100 mm tissue culture plates,
at approximately 60% confluency, with 5 µg of minigene2-pcDNA4A vector with
MegaTran 1.0 according to the manufacturer’s protocol.
SH-SY5Y cells were transfected in 100 mm tissue culture plates, at approximately
70% confluency, with 6 µg of minigene2-pcDNA4A, 18 µL of Lipofectamine 2000
(Invitrogen), 6 µL Plus reagent in 1 mL of Opti-MEM, as per the manufacturer’s
protocol.

2.5 RNA Extraction and Subsequent DNase Treatment of RNA

Total RNA was extracted from cells using Isol-RNA Lysis Reagent (5Prime),
according to the manufacturer’s protocol. RNA was DNase treated using RQ1 RNasefree DNase (Promega) for 2 hours at 37°C. Following DNase treatment, the RNA
samples were phenol/chloroform extracted, precipitated, and re-suspended in DEPC
(Sigma)-treated H2O. RNA concentrations were measured using a Nanodrop 2000
spectrophotometer (Thermo Scientific).
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2.6 Reverse Transcriptase-Polymerase Chain Reaction

RT-PCR was carried out using a OneStep RT-PCR Kit (Qiagen), following the
manufacturer’s protocol. 1 µg of RNA was used for all RT-PCR experiments.
The primer sequences that were used can be found in Table 2.1. Thermocycling
conditions used for all reactions were: reverse transcription at 50°C for 30 minutes,
activation of Taq polymerase at 95°C for 15 minutes, 40 cycles of denaturation at 94°C
for 30 seconds, annealing at 55°C for 1 minute, and extension at 72°C for 1 minute, and a
final extension at 72°C for ten minutes. The RT-PCR products were resolved on 1%
agarose gels containing 0.5 µg/mL ethidium bromide. Also, a no template control (NTC)
was run as a negative control, to indicate reagent or cross contamination of experimental
samples.

2.7 Real-Time Quantitative RT-PCR

Quantitative expression analyses of minigene and endogenous TAFI transcripts
were carried out on a BioRad CFX96 Real-Time System. Probes were labeled at the 5’end with the reporter FAM (6-carboxyfluorescein), and at the 3’ end with a
nonfluorescent quencher that was bound to a minor groove binder (NFQ-MGB). The
primer and probe sequences used can be found in Table 2.4. In 96-well optical plates
(BioRad), 10 µL of 2× QRT-PCR Master Mix (Brilliant III Ultra-Fast QRT-PCR Master
Mix - Agilent) (final concentration 1×), 0.2 µL DTT (final concentration 1 mM), and 1
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Table 2.4. Probe and Primer Sequences Used For Real-Time RT – PCR
Primer Name

	
  

Sequence (5’ à 3’)

FL M1 - 5’ Primer

GGA TTT CTA TGT TAT GCC GG

FL M1 - 3’ Primer

GAT TGT TCG CAT AGA AAG AAC

FL M1 Probe

56-FAM/CCACATTCG/ZEN/ATTCTTTTTCC
ATGAGTAGTCATAACCGTCC/3IABkFQ/

∆7 - 5’ Primer

ATG GAT TGA CTG TGG AAT CC

∆7 – 3’ Primer

GAT TGT TCG CAT AGA AAG AAC

∆7 Probe

56-FAM/CCACATTCG/ZEN/ATTATGGCCT
ATGAACCAGCAGAAAGCAGG/3IABkFQ

∆7+8 – 5’ Primer

ATG GAT TGA CTG TGG AAT CC

∆7+8 – 3’ Primer

TGG TTC TGA CTC AGG ATA AAG

∆7+8 Probe

56-FAM/CATGAGGAA/ZEN/CTGGATGCACCTT
CCTATGGCCTATGAACCACAAGC/3IABkFQ

∆11 – 5’ Primer

CTG GAG GTG GGG ACG ATT G

∆11 – 3’ Primer

CAG CGG CAA AAG CTT CTC

∆11 Probe

56-FAM/GTGGGTTTG/ZEN/ATGTAAACGAA
TATTTGATGCCCAAATCATAG/3IABkFQ

FL M2 – 5’ Primer

GGG ACG ATT GGA TCT ATG ATT TGG GCA TC

FL M2 – 3’ Primer

TAC ATG CCA AGC TAT TTT AGA GAC AGC GGC

FL M2 Probe

56-FAM/CCGGCAGCA/ZEN/AGAATCCGTATGT
GCCCGTATCTCGAAGTTCAATTG /3IABkFQ
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µL RT/RNase Block were added to total RNA, and 1 µL of forward and reverse primers
and probe (final concentrations: 300 nM each primer; 200 nM probe). Thermal cycling
conditions used for all reactions were: reverse transcription at 50°C for 30 minutes,
activation of Taq polymerase at 95°C for 15 minutes, 40 cycles of denaturation at 94°C
for 30 seconds, annealing at 55°C for 1 minute, and extension at 72°C for 1 minute, and a
final extension at 72°C for ten minutes. A no-reverse transcriptase (NRT) control was
performed as well to check for genomic or plasmid DNA contamination in the RNA
samples. This control was carried out similarly to the sample reactions, except that
RT/RNase Block was not included in the control. Furthermore, a no-template control
(NTC) was included as well, to control for reagent or cross contamination of
experimental samples.
The DNA standards used for absolute quantitation were generated by first
spectrophotometrically determining the DNA concentration of the appropriate plasmid,
followed by converting the DNA concentrations into the number of transcripts by using
the calculated molecular mass of the DNA. The DNA standards were then serially diluted
10-fold, so that a series of standards containing 102-109 copies/ µL was achieved.
Aliquots were stored at 4°C prior to use.
	
  

2.8 Metabolic Labeling of Cells

2.8.A. Steady-State Labeling
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HepG2 and BHK cells were seeded into 60 mm tissue culture dishes and cultured
to 60% confluency. They were then transiently transfected using Megatran 1.0
(DNA:Megatran 1:3) with 4 µg of each plasmid (pcDNA4A, FL TAFI-4A, Δ7-4A, Δ114A, Δ7+11-4A) each respectively into one 60 mm dish. Also, a non-transfected control
was included as a negative control. Twenty-four hours post transfection, the cells were
washed two times with 3 mL of PBS (10 mM Na2HPO4, 2.7 mM KCl, 137 mM NaCl,
1.76 mM KH2PO4, pH 7.4), fresh complete growth medium was applied to the plates and
cells were allowed to recover overnight. On the following day, the medium was removed
from the plates and the cells were washed two times with 3 mL of PBS; then, 2 mL of
Cys/Met-free DMEM (Gibco) was added to the plates for one hour. Next, 300 µCi of
[35S] Cys/ [35S] Met labeling mix (Perkin Elmer Life Sciences) was added to each plate,
and protein labeling was allowed to occur overnight. 18 hours post labeling, both the
media and lysates were harvested.
Following media collection, plates were washed two times with 5 mL of ice cold
PBS. Next, 1 mL of V4 Lysis Buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA,
1% NP-40, 0.25% sodium deoxycholate) was added to each plate, and plates were shaken
at 4°C for ten minutes at high speed. The lysates were then collected and centrifuged at
16,000 × g for 5 minutes to clear the samples. Media samples were also briefly
centrifuged at 700 × g to clear the samples.
Media and lysate samples were rocked overnight with 3 µg of monoclonal mouseanti-myc antibody (Santa Cruz) at 4°C. The next day, recombinant protein G agarose
(Invitrogen) (at 30 µL/mL) was added to the sample containing the antibody, and rocked
at 4°C for another 2 hours. Samples were then washed one time with RIPA
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(Radioimmunoprecipitation assay) buffer (50mM Tris pH 7.4, 150 mM NaCl, 20 mM
EDTA, 1% sodium deoxycholate, and 0.1% SDS), and washed two times with PBS, and
finally suspended in Laemmli sample buffer. Samples were briefly centrifuged to pellet
the agarose, boiled for 5 minutes, and then briefly centrifuged again before loading each
sample onto a 12% polyacrylamide gel for SDS-PAGE.
Following electrophoresis, the gels were gently rocked at room temperature in
fixing solution (isopropanol:H2O:glacial acetic acid 25:65:10) for 20 minutes, and then
briefly rinsed with H2O, before gently rocking in Amplify solution (Amersham
Biosciences) for 20 minutes. Next, gels were dried using a gel dryer (BioRad Model 583)
on cycle 2 at 80°C for 35 minutes.
Radioactive ink was prepared by adding 50 µCi of [35S] Cys/ [35S] Met labeling
mix (Perkin Elmer Life Sciences) to 400 µL of Super Black India ink, which was applied
to the pre-labeled protein ladder using a felt-tip pen. A layer of clear plastic tape was
placed on top of the ink to protect the screen.
Lastly, gels were exposed to a phosphor K screen (BioRad) at room temperature
for 90 hours before screens were imaged using a BioRad Molecular Imager FX
phosphorimager.

2.8.B. Pulse-Chase Labeling

HepG2 cells were seeded into 60 mm tissue culture dishes and cultured to 60%
confluency. They were then transfected using Megatran 1.0 (DNA:Megatran 1:3) with 4
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µg of each plasmid (FL TAFI-4A or Δ7-4A) each respectively into one 60 mm dish.
Also, a non-transfected control was included as a negative control. 24 hours post
transfection, the cells were washed two times with 3 mL of PBS; fresh complete growth
media was applied to the plates and cells were allowed to recover overnight. On the
following day, the medium was removed from the plates; the cells were washed two
times with 3 mL of PBS, and then 2 mL of Cys/Met-free DMEM (Gibco) was added to
the plates for 45 minutes. Next, 300 µCi of [35S] Cys/ [35S] Met labeling mix (Perkin
Elmer Life Sciences) was added to each plate, and protein labeling was allowed to occur
for 1 hour. Next, the labeled media was removed from the plates, cells were washed two
times with 3 mL of PBS, and then complete unlabeled growth medium was added to the
plates. Both the media and lysates were harvested from plates at the following time
points: 0 hr, 15 min, 30 min, 1 hr, 2 hr, 4 hr and 6 hr.
Following media collection, plates were washed two times with 5 mL of ice cold
PBS. Next, 1 mL of V4 Lysis Buffer was added to each plate, and plates were shaken at
4°C for ten minutes at high speed. The lysate was then collected and centrifuged at
16,000 × g for 5 minutes to clear the sample. Media samples were also briefly centrifuged
at 700 × g to clear samples. Immunoprecipitations with the anti-myc antibody, SDSPAGE, and fluorography were carried out as described above in Section 2.8.A.

	
  

	
  

68

Chapter 3: Results

3.1 Identification of Minigene CPB2 mRNA in Several Cell Types Using RT-PCR

The expression of pCMV-minigene CPB2 mRNA was evaluated in several cell
types via RT-PCR. The cell types that were investigated included HepG2 (human
hepatocellular carcinoma) cells, BHK (baby hamster kidney) cells, Hek293 (human
embryonic kidney) cells, THP-1 (human acute monocytic leukemia) cells, and SH-SY5Y
(neuroblastoma) cells. The primer set used was the 5’-EGFP 5’ primer, and the 3’-EGFP
3’ primer (For primer sequences, see Table 2.1). The projected fragment sizes were 841
bp for full length minigene1, 730 bp for Δ7 minigene1, and 636 bp for Δ7+8 minigene1,
and 597 bp for full length minigene2, and 545 bp for Δ11 minigene2. The RT-PCR
results using this primer set are displayed in Figure 3.1.A for minigene1 and Figure 3.1.B
for minigene2.
The anticipated fragment sizes for full length minigene1, Δ7 minigene1, and
Δ7+8 minigene1 were only present in the HepG2 and Hek293 cell lines while no bands
appeared for the SH-SY5Y or THP-1 cell lines (Figure 3.1.A). In addition, the NTC lane
was empty; therefore, the bands present in the gel can be assumed to be bona fide
fragments, and not as a result from contamination of the reactions from the reagents or
plasmid DNA. Thus, splicing of the transcripts from minigene1 occurred at the expected
location in these two cell types. In the HepG2 cells, the Δ7+8 transcript appears to be
more abundant than the full length, and Δ7 transcript. In the Hek293 cells, the full length
transcript appears to be the dominant species present, and the splice variants appear to be
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Figure 3.1. Detection of Minigene1-4A and Minigene2-4A mRNA Using EGFP
Primer Set.
One Step RT-PCR was conducted on total RNA extracts from HepG2, BHK, Hek293,
THP-1 and SH-SY5Y cells transfected with pCMV-minigene1-4A (A.) or pCMVminigene2-4A (B.), using 5’ EGFP 5’ – Primer and 3’ EGFP 3’- Primer set. The products
from the RT-PCR reaction were run on a 1% agarose gel. The arrows indicate the band of
the predicted alternatively spliced amplification products of each respective minigene. A
No Template Control (NTC) reaction was also run that did not have an RNA template to
serve as a negative control.
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of approximately equal intensity (Figure 3.1.A). No bands of the correct size were
detected in SH-SY5Y or differentiated THP-1 cells. It appears likely that in this
experiment the minigene1 plasmid was not transfected into the cells.
The anticipated fragment size for full length minigene2 was present in all cell
lines investigated (Figure 3.1.B). Once again, the NTC lane was empty. With respect to
the Δ11 minigene2 version, no bands of the correct size were observed (Figure 3.1.B). In
addition, two other prominent bands appeared, one at approximately 1300 bp and another
at approximately 1500 bp. These bands may correspond to incompletely spliced variants
of minigene2, since the minimum size of the un-spliced full length minigene2 fragment is
597 bp.

3.2 Quantification of Endogenous and Minigene CPB2 mRNA in Several Cell Types
via Real Time RT-PCR

Once CPB2 mRNA corresponding to full length minigene2, as well as full length
and alternatively spliced minigene1 were identified in several cell types, real time RTPCR was performed to quantify the extent of alternative splicing within these various cell
lines that occurs endogenously in comparison to that observed for transcripts expressed
from the minigenes. Real time PCR is a more quantitative and sensitive method than RTPCR, thus it was employed to detect the low copy number that is endogenously expressed
by alternatively spliced CPB2 transcripts. The probe and primer sets used can be found in
Table 2.4, the standard curves generated from the standards can be found in Figures 3.2-
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3.6, the final results from the real time RT-PCR can be found in Figures 3.7-3.11, and a
summary table of all the results can be found in Table 3.1.
With respect to endogenous and minigene1 data (Figure 3.7), endogenous full
length CPB2 mRNA was detected in all cell types investigated, except Hek293, as was
expected. In contrast, minigene1 full length CPB2 mRNA was detected in all cell types
investigated (HepG2, Hek293, SH-SY5Y, and differentiated THP-1). With respect to Δ7
endogenous and minigene1 data (Figure 3.8), endogenous Δ7 CPB2 mRNA was detected
in all cell types investigated, except Hek293, as was expected. In contrast, Δ7 minigene1
CPB2 mRNA was detected in all cell types investigated. It is also important to note that
Δ7 minigene1 accounted for greater than 50% of all the transcripts detected that were
alternatively spliced from minigene1 across all cell types investigated (Table 3.1). With
respect to Δ7+8 endogenous and minigene1 data (Figure 3.9), endogenous Δ7+8 CPB2
mRNA was detected in HepG2 and differentiated THP-1 cells, but not in Hek293 (as was
expected) or SH-SY5Y cells. In contrast, Δ7+8 minigene1 CPB2 mRNA was detected in
all cell types investigated. Therefore, in all cell types examined, minigene1 was correctly
spliced into full-length, and alternatively spliced Δ7 minigene1, and Δ7+8 minigene1.
With respect to endogenous and minigene2 data (Figure 3.10), endogenous full
length CPB2 mRNA was detected in HepG2 cells and SH-SY5Y cells, but not in BHK or
Hek293 cells, as was expected. In contrast, minigene2 full length CPB2 mRNA was
detected in all cell types investigated (HepG2, BHK, Hek293 and SH-SY5Y). With
respect to Δ11 endogenous and minigene2 data (Figure 3.11), endogenous Δ11 CPB2
mRNA was detected in HepG2 cells and also in SH-SY5Y cells, but not BHK or Hek293,
as was expected. In contrast, Δ11 minigene2 CPB2 mRNA was detected in all cell types.
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Figure 3.2. Standard Curve of Full Length CPB2 Standards for Full Length
Endogenous CPB2 and Full Length Minigene1 Absolute Quantification for Real
Time PCR Analysis.
To determine the number of full length CPB2 target transcripts present in unknown
samples, standard curves were created by serially diluting full length TAFI + pBluescript
SK II + plasmid 10 fold so that a series of 102-108 copies/uL were achieved. These
samples were used as a template and subjected to real time quantitative RT-PCR along
with RNA samples extracted from HepG2, Hek293, SH-SY5Y and differentiated THP-1
cells not transfected and transfected with minigene1-4A. The standard curve shown
represents the relationship between the threshold cycle (Ct) and the log amount of
standard input. This primer and probe set was designed to amplify a linker region
between exon 7 and exon 8 of CPB2. Each value was calculated from the mean ±
standard error of the mean (SEM) of three independent experiments performed in
triplicates.
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Figure 3.3. Standard Curve of Δ7 CPB2 Standards for	
  Δ7 Endogenous CPB2 and Δ7
Minigene1 Absolute Quantification for Real Time PCR Analysis.
To determine the number of Δ7 CPB2 target transcripts present in unknown samples,
standard curves were created by serially diluting Δ7 TAFI + pBluescript SK II + plasmid
10 fold so that a series of 101-108 copies/uL were achieved. These samples were used as a
template and subjected to real time quantitative RT-PCR along with RNA samples
extracted from HepG2, Hek293, SH-SY5Y and differentiated THP-1 cells not transfected
and transfected with minigene1-4A. The standard curve shown represents the relationship
between the threshold cycle (Ct) and the log amount of standard input. This primer and
probe set was designed to amplify the end of exon 6 in conjunction with the beginning of
exon 8 of CPB2. Each value was calculated from the mean ± standard error of the mean
(SEM) of three independent experiments performed in triplicates.
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Figure 3.4. Standard Curve of Δ7+8 CPB2 Standards for	
  Δ7+8 Endogenous CPB2
and Δ7+8 Minigene1 Absolute Quantification for Real Time PCR Analysis.
To determine the number of Δ7+8 CPB2 target transcripts present in unknown samples,
standard curves were created by serially diluting Δ7+8 TAFI + pBluescript SK II +
plasmid 10 fold so that a series of 101-108 copies/uL were achieved. These samples were
used as a template and subjected to real time quantitative RT-PCR along with RNA
samples extracted from HepG2, Hek293, SH-SY5Y and differentiated THP-1 cells not
transfected and transfected with minigene1-4A. The standard curve shown represents the
relationship between the threshold cycle (Ct) and the log amount of standard input. This
primer and probe set was designed to amplify the end of exon 6 in conjunction with the
beginning of exon 9 of CPB2. Each value was calculated from the mean ± standard error
of the mean (SEM) of three independent experiments performed in triplicates.
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Figure 3.5. Standard Curve of Full Length CPB2 Standards for Full Length
Endogenous CPB2 and Full Length Minigene2 Absolute Quantification for Real
Time PCR Analysis.
To determine the number of full length CPB2 target transcripts present in unknown
samples, standard curves were created by serially diluting full length TAFI + pBluescript
SK II + plasmid 10 fold so that a series of 102-108 copies/uL were achieved. These
samples were used as a template and subjected to real time quantitative RT-PCR along
with RNA samples extracted from HepG2, BHK, Hek293, and SH-SY5Y cells not
transfected and transfected with minigene2-4A. The standard curve shown represents the
relationship between the threshold cycle (Ct) and the log amount of standard input. This
primer and probe set was designed to amplify within the 52 bp region of exon 11
normally deleted in Δ11 TAFI of CPB2. Each value was calculated from the mean ±
standard error of the mean (SEM) of three independent experiments performed in
triplicates.
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Figure 3.6. Standard Curve of Δ11 CPB2 Standards for Δ11 Endogenous CPB2 and
Δ11 Minigene2 Absolute Quantification for Real Time PCR Analysis.
To determine the number of Δ11 CPB2 target transcripts present in unknown samples,
standard curves were created by serially diluting Δ11 TAFI + pBluescript SK II +
plasmid 10 fold so that a series of 101-108 copies/uL were achieved. These samples were
used as a template and subjected to real time quantitative RT-PCR along with RNA
samples extracted from HepG2, BHK, Hek293, and SH-SY5Y cells not transfected and
transfected with minigene2-4A. The standard curve shown represents the relationship
between the threshold cycle (Ct) and the log amount of standard input. This primer and
probe set was designed to amplify a region within exon 11 that conjoins the flanking
regions on either side of the 52 bp region in exon 11 that is normally deleted in Δ11 TAFI
of CPB2. Each value was calculated from the mean ± standard error of the mean (SEM)
of three independent experiments performed in triplicates.
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Figure 3.7. Quantitative Analysis of Endogenous and Minigene1 Full Length CPB2
mRNA in Several Cell Types
The abundance of full length endogenous and full length minigene1 CPB2 mRNA
transcripts was assessed from total RNA isolated from not transfected and transfected
HepG2, Hek293, SH-SY5Y and differentiated THP-1 cells with minigene1-4A using
quantitative real time RT-PCR. The primer and probe set was designed to amplify a
linker region between exon 7 and exon 8 of CPB2. The quantity of unknown samples was
determined via extrapolation from the full-length CPB2 minigene1 standard curve. Each
value was calculated from the mean ± standard error of the mean (SEM) of three
independent experiments performed in triplicates.
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Figure 3.8. Quantitative Analysis of Endogenous and Minigene1 Δ7 CPB2 mRNA in
Several Cell Types.
The abundance of Δ7 endogenous and Δ7 minigene1 CPB2 mRNA transcripts was
assessed from total RNA isolated from not transfected and transfected HepG2, Hek293,
SH-SY5Y and differentiated THP-1 cells with minigene1-4A using quantitative real time
RT-PCR. The primer and probe set was designed to amplify the end of exon 6 in
conjunction with the beginning of exon 8 of CPB2. The quantity of unknown samples
was determined via extrapolation from the Δ7 CPB2 minigene1 standard curve. Each
value was calculated from the mean ± standard error of the mean (SEM) of three
independent experiments performed in triplicates.
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Figure 3.9. Quantitative Analysis of Endogenous and Minigene1 Δ7+8 CPB2 mRNA
in Several Cell Types.
The abundance of Δ7+8 endogenous and Δ7+8 minigene1 CPB2 mRNA transcripts was
assessed from total RNA isolated from not transfected and transfected HepG2, Hek293,
SH-SY5Y and differentiated THP-1 cells with minigene1-4A using quantitative real time
RT-PCR. The primer and probe set was designed to amplify the end of exon 6 in
conjunction with the beginning of exon 9 of CPB2. The quantity of unknown samples
was determined via extrapolation from the Δ7+8 CPB2 minigene1 standard curve. Each
value was calculated from the mean ± standard error of the mean (SEM) of three
independent experiments performed in triplicates.
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Figure 3.10. Quantitative Analysis of Endogenous and Minigene2 Full Length CPB2
mRNA in Several Cell Types.
The abundance of full length endogenous and full length minigene2 CPB2 mRNA
transcripts was assessed from total RNA isolated from not transfected and transfected
HepG2, BHK, Hek293, and SH-SY5Y cells with minigene2-4A using quantitative real
time RT-PCR. The primer and probe set was designed to amplify within the 52 bp region
of exon 11 normally deleted in Δ11 TAFI of CPB2. The quantity of unknown samples
was determined via extrapolation from the full length CPB2 minigene2 standard curve.
Each value was calculated from the mean ± standard error of the mean (SEM) of three
independent experiments performed in triplicates.
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Figure 3.11. Quantitative Analysis of Endogenous and Minigene2 Δ11 CPB2 mRNA
in Several Cell Types.
The abundance of Δ11 endogenous and Δ11 minigene2 CPB2 mRNA transcripts was
assessed from total RNA isolated from not transfected and transfected HepG2, BHK,
Hek293, and SH-SY5Y cells with minigene2-4A using quantitative real time RT-PCR.
The primer and probe set was designed to amplify a region within exon 11 that conjoins
the flanking regions on either side of the 52 bp region in exon 11 that is normally deleted
in Δ11 TAFI of CPB2. The quantity of unknown samples was determined via
extrapolation from the Δ11 CPB2 minigene2 standard curve. Each value was calculated
from the mean ± standard error of the mean (SEM) of three independent experiments
performed in triplicates.
	
  
	
  

	
  

82

Table 3.1. Summary Tables of Real Time PCR Analysis of Full Length CPB2 and
Alternatively Spliced Minigene CPB2 Variants.
Each value was calculated from the mean ± standard error of the mean (SEM)
of three independent experiments performed in triplicate.
A.	
  
Sample

(FL/Total) (%)

(Δ7/Total) (%)

(Δ7+8/Total) (%)

Sum (%)

HepG2

88.54

0.22

11.24

100

HepG2 Mini1

33.47

54.73

11.80

100

Hek293

0

0

0

0

Hek293 Mini1

42.98

50.96

6.06

100

SH-SY5Y

45.43

54.57

0

100

SH-SY5Y Mini1

24.76

53.82

21.42

100

THP-1

65.34

26.30

8.36

100

THP-1 Mini1

15.36

57.70

26.94

100

	
  
B.	
  
	
  

	
  

Sample

(FL/Total) (%)

(Δ11/Total) (%)

Sum (%)

HepG2

99.57

0.43

100

HepG2 Mini2

75.92

24.08

100

BHK

0

0

0

BHK Mini2

77.41

22.59

100

Hek293

0

0

0

Hek293 Mini2

97.10

2.90

100

SH-SY5Y

96.75

3.25

100

SH-SY5Y Mini2

19.85

80.15

100
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Concerning the cell types that endogenously express TAFI (HepG2, SH-SY5Y,
and THP-1 cells), the following trend (from most abundant to least abundant transcript
number) was observed: HepG2 (full length > Δ7+8 > Δ7), SH-SY5Y (Δ7 > full length;
Δ7+8 not detected and/or not expressed), differentiated THP-1 cells (full length > Δ7 >
Δ7+8). With regard to minigene1 data, the following trend was observed in HepG2 and
SH-SY5Y cells: (Δ7 > full length > Δ7+8), while the following trend was observed in
differentiated THP-1 cells: (Δ7 > Δ7+8 > full length). With regard to minigene2 data, the
following trend was observed in all cell types examined: (full length > Δ11), except in
SH-SY5Y. Overall, there are considerable discrepancies in the proportions of the
alternatively spliced forms when comparing the endogenous transcripts to those encoded
by the minigenes (Table 3.1).

3.3 Identification of Full Length and Alternatively Spliced TAFI Variants via
Metabolic Labeling

Identification of TAFI protein that is translated from alternatively spliced CPB2
mRNA was executed via metabolic labeling. First, steady state metabolic labeling was
performed on HepG2 and BHK cells. Briefly, cells were transiently transfected with
pcDNA4A, Full length TAFI-4A, Δ7 TAFI-4A, Δ11 TAFI-4A, or Δ7+11 TAFI-4A
plasmids and labeled with 35S -(Cys/Met); conditioned medium and lysates were prepared
and immunoprecipitated with a mouse monoclonal anti-myc antibody, and the
immunoprecipitates were subjected to SDS-PAGE and fluorography. As a positive
control, BHK cells were transfected with the full-length-4A plasmid and
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immunoprecipitations of the medium and lysate were performed with a polyclonal sheep
anti-TAFI antibody. The steady state metabolic labeling results are shown in Figure 3.12
for HepG2 cells, and Figure 3.13 for BHK cells.
TAFI has an apparent MW of approximately 60 kDa on SDS-PAGE (26).
However, due to the addition of the myc-6× His tag in the pcDNA4A plasmid, the MW
of TAFI appears slightly larger, at approximately 63 kDa. In the HepG2 media, a distinct
full-length TAFI band of approximately 63 kDa was observed only for full length TAFI
(Figure 3.12.A). In the BHK media, a distinct full length TAFI band of approximately 63
kDa was only observed for the full-length TAFI sample that was immunoprecipitated
with the anti-TAFI antibody, but not with the anti-myc antibody (Figure 3.13.A). No
bands corresponding to protein from any of the alternatively spliced transcripts were
observed in the media of HepG2 or BHK cells.
In the HepG2 lysates (Figure 3.12.B), two distinct bands appear in the full length
TAFI lane, one of approximately 63 kDa which corresponds to the mature, fullyglycosylated form of TAFI, and a band of approximately 53 kDa which likely
corresponds to a hypo-glycosylated form of TAFI (Figure 3.12.B). In addition, a band of
approximately 51 kDa is also present that corresponds to the Δ7 TAFI variant (Figure
3.12.B). In the BHK lysates, only one distinct band appears in the full length TAFI lane
(immunoprecipitated with anti-myc antibody and with the anti-TAFI antibody) of
approximately 53 kDa, which corresponds to the hypo-glycosylated form of TAFI
(Figure 3.13.B.). In addition, a band of approximately 51 kDa is also present that
corresponds to the Δ7 TAFI variant (Figure 3.13.B).
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Once alternatively spliced TAFI corresponding to the Δ7 TAFI variant was
detected in HepG2 cells via steady state metabolic labeling, pulse-chase labeling was
employed to determine the fate of the alternatively spliced protein Pulse labeling of
HepG2 cells was carried out similarly to steady state labeling. However, a 6-hour chase
time course was used to determine the point of degradation of the alternatively spliced
transcript.
In the lysates of pulse chased 35S-labeled HepG2 cells transfected with full length
TAFI, only the hypo-glycosylated form of TAFI is present between 0 and 30 minutes
(Figure 3.14.B). At one hour, both the hypo-glycosylated and glycosylated forms of TAFI
are present in the lysate (Figure 3.14.B). In addition, in the media, there is a burst of
secretion of full length TAFI after one hour, which is sustained through 6 hours (Figure
3.14.A).
In the lysates of 35S-pulse-labeled and chased HepG2 cells transfected with Δ7
TAFI, only the hypo-glycosylated form of the Δ7 TAFI variant is observed (Figure
3.15.B). This variant is present between 0 and 2 hours of chase, after which it disappears,
which is indicative of its degradation in the lysate (Figure 3.15.B). The Δ7 TAFI variant
is never secreted into the media like full length TAFI (Figure 3.14.A), as evidenced by
the lack of bands in the media of the Δ7 TAFI variant during the 6 hour pulse chase time
course (Figure 3.15.A). Moreover, a fully-glycosylated intracellular form is never
observed (Figure 3.15.B).
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Figure 3.12. Identification of Full Length and Alternatively Spliced TAFI Variants
in HepG2 Cells Using Steady State Metabolic Labeling and Immunoprecipitation.
HepG2 cells were transiently transfected with pcDNA4A, FL-4A, Δ7-4A, Δ11-4A, and
Δ7+11-4A. Also, a non-transfected plate of HepG2 cells was used as a negative control.
18 hours post transfection fresh media was added to the plates and cells were allowed to
recover overnight. The following day Cys/Met-free DMEM was added to the plates for
one hour, then [35S] Cys/ [35S] Met labeling mix was added to the plates and protein
labeling occurred overnight. Next, both the media (A.) and lysate (B.) samples were
harvested and subjected to immunoprecipitation with a monoclonal mouse-anti-myc
antibody. Lastly, proteins were separated on a 12% polyacrylamide SDS-PAGE, fixed,
dried and exposed to a phosphor imaging screen for 90 hours at room temperature before
imaging.
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Figure 3.13. Identification of Full Length and Alternatively Spliced TAFI Variants
in BHK Cells Using Steady State Metabolic Labeling and Immunoprecipitation.
BHK cells were transiently transfected with pcDNA4A, FL-4A, Δ7-4A, Δ11-4A, and
Δ7+11-4A. Also, a non-transfected plate of BHK cells was used as a negative control,
and a second plate was transfected with FL-4A to serve as a positive control. 18 hours
post transfection fresh media was added to the plates and cells were allowed to recover
overnight. The following day Cys/Met-free DMEM was added to the plates for one hour,
then [35S] Cys/ [35S] Met labeling mix was added to the plates and protein labeling
occurred overnight. Next, both the media (A.) and lysate (B.) samples were harvested and
subjected to immunoprecipitation with a monoclonal mouse-anti-myc antibody. The
BHK positive control used a polyclonal sheep-anti TAFI antibody for
immunoprecipitation instead. Lastly, proteins were separated on a 12% polyacrylamide
SDS-PAGE, fixed, dried and exposed to a phosphor imaging screen for 90 hours at room
temperature before imaging.
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Figure 3.14. Identification of Full Length TAFI in HepG2 Cells Using Pulse Chase
Metabolic Labeling and Immunoprecipitation.
HepG2 cells were transiently transfected with FL-4A. Also, a non-transfected plate of
HepG2 cells was used as a negative control. 18 hours post transfection fresh media was
added to the plates and cells were allowed to recover overnight. The following day
Cys/Met-free DMEM was added to the plates for one hour, then [35S] Cys/ [35S] Met
labeling mix was added to the plates and protein labeling occurred for one hour. Next,
both the media (A.) and lysate (B.) samples were harvested at selected time points (0 hr,
15 mins, 30 mins, 1 hr, 2 hr, 4 hr and 6 hr) and subjected to immunoprecipitation with a
monoclonal mouse-anti-myc antibody. Lastly, proteins were separated on a 12%
polyacrylamide SDS-PAGE, fixed, dried and exposed to a phosphor imaging screen for
90 hours at room temperature before imaging.
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Figure 3.15. Identification of Δ7 TAFI in HepG2 Cells Using Pulse Chase Metabolic
Labeling and Immunoprecipitation.
HepG2 cells were transiently transfected with Δ7-4A. Also, a non-transfected plate of
HepG2 cells was used as a negative control. 18 hours post transfection fresh media was
added to the plates and cells were allowed to recover overnight. The following day
Cys/Met-free DMEM was added to the plates for one hour, then [35S] Cys/ [35S] Met
labeling mix was added to the plates and protein labeling occurred for one hour. Next,
both the media (A.) and lysate (B.) samples were harvested at selected time points (0 hr,
15 mins, 30 mins, 1 hr, 2 hr, 4 hr and 6 hr) and subjected to immunoprecipitation with a
monoclonal mouse-anti-myc antibody. Lastly, proteins were separated on a 12%
polyacrylamide SDS-PAGE, fixed, dried and exposed to a phosphor imaging screen for
90 hours at room temperature before imaging.
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Chapter 4: Discussion

4.1 Alternative Splicing and Its Role in the Regulation of CPB2 Gene Expression

Most mammalian genes consist of several short coding exonic regions that are
intervened by much larger non coding intronic regions (91). To produce a mature mRNA
species, the exons must first be recognized, followed by the removal of the intronic
regions, and precise ligation of the exons together (91). Alternative splicing (AS) is a
common cellular mechanism in higher eukaryotes that allows for the production of
multiple mRNA isoforms from a single gene (92). This mechanism occurs in
approximately 90% of all human multi-exon genes (92). Alternative splicing of premRNA transcripts takes place at a very crucial point in the flow of genetic information
between transcription and translation. Alternative splicing is carried out by the
spliceosome, a multi ribonucleoprotein complex that assembles at recognized splice sites
within a pre-mRNA sequence (92). The core of the spliceosome consists of five small
nuclear RNAs, snRNAs (U1, U2, U4, U5, and U6 snRNA), in combination with over 150
proteins (92).
Splice sites consist of a consensus splice sequence (GU at the 5’ splice site and
AG at the 3’ splice site), which are recognized by various splicing factors (92). The
differential combination of competing 5’ and 3’ splice sites results in the production of
alternatively spliced mature mRNA transcripts, through the inclusion/exclusion of an
intron sequence, inclusion/exclusion of an exon sequence, or lengthening or shortening of
an exon sequence (92). The proteins that are translated from these alternatively spliced
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mRNA transcripts also have the potential to gain new protein functions, lose protein
functions, or evolve into new, related protein functions. Thus, through the process of
alternative splicing, the protein coding capacity of the eukaryotic genome is substantially
increased without having to change the sequence of the original genomic code.
In the human population, the plasma TAFI antigen levels can vary significantly
between different individuals. Currently, genetic effects on the gene encoding TAFI,
CPB2, can only explain 15-25% of this differential variation in gene expression by
individuals. Thus, the majority of factors that contribute to the regulation of CPB2 gene
expression are still largely unknown. The main source of plasma TAFI is produced by the
liver; however, recent studies have shown that TAFI is also extra-hepatically expressed in
various other sites, such as the brain (cerebellum, cortex, hippocampus), testis, platelets,
and immune and hematopoietic cells (89). Furthermore, the discovery of the numerous
alternatively spliced TAFI variations has added a new level of complexity to the
regulation of CPB2 gene expression by alternative splicing mechanisms.
The main concepts underlying the present study was that alternative splicing of
CPB2 takes place by cell specific regulation processes that leads to different populations
of alternatively spliced transcripts being expressed in different cell types, and that these
transcripts have the potential to evolve into new, and distinct functions from full length
TAFI. To study the extent of alternative splicing within various immune and vascular cell
types, a minigene approach was employed. A minigene is a modified version of a
naturally occurring gene that lacks one or more of its usual introns or exons. The use of
minigenes as model systems to study splicing events is advantageous because it exploits
the cells natural splicing and transcription machinery to investigate splicing events. Also,
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the use of minigenes to study alternative splicing events has proven to be an effective
strategy in the analysis of other alternatively spliced genes (93, 94, 95, 96).
In this study, we were able to successfully characterize, in a quantitative manner,
the alternative splicing events occurring in various immune and vascular cell types. As
was anticipated, the real time RT-PCR results revealed that alternative splicing of CPB2
is regulated in a cell-specific manner. All the cell types examined contained different
populations of full length and alternatively spliced endogenous CPB2 transcripts. In
addition, the abundance of each transcript varied significantly between the different cell
types. We can therefore conclude that the extent of alternative splicing of CPB2 premRNA occurs in a cell type-specific manner. We also found that the full spectrum of
alternative splicing events could be recapitulated using the minigene approach; on the
other hand, the frequency of the different splicing events differed substantially between
the endogenous and minigene CPB2 transcripts. Our studies of the expression and
intracellular processing of TAFI variants arising from alternative splicing confirm that
these variants cannot be secreted and show differences in their intracellular trafficking
kinetics.
In sum, these discoveries improve our understanding of CPB2 alternative splicing
events. The knowledge gained from this study will eventually aid us in delineating the
pathways by which alternative splicing events determine whether a pre-mRNA CPB2
transcript will become a full length TAFI variant involved in hemostasis or an
alternatively spliced transcript, whose function remains to be discovered.
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4.2 Identification of Minigene CPB2 mRNA in Several Cell Types via RT-PCR

Upon completing assembly of each minigene, they were transiently transfected into
the cell types of interest to determine if mRNA that was transcribed from them could be
detected. For this purpose, we employed RT-PCR using the 5’ EGFP – 5’ primer and the
3’ EGFP – 3’ primer. For minigene1, the expected amplicon lengths were: 841 bp for full
length minigene1, 730 bp for Δ7 minigene1, and 636 bp for Δ7+8 minigene1; for
minigene2, the expected amplicon lengths were 597 bp for full length minigene2 and 545
bp for Δ11 minigene2. The results from the RT-PCR analysis clearly reveal that
minigene1 was correctly spliced into full length minigene1, Δ7 minigene1, and Δ7+8
minigene1 in HepG2 and Hek293 cells. This was evident by the detection of the expected
fragment sizes for full length, Δ7, and Δ7+8 minigene1. The fact that all three variants
were found in HepG2’s is in accordance with what has been previously published for this
cell line (89). TAFI is not endogenously expressed in Hek293 cells, and so it is notable
that the cells’ splicing machinery was able to splice minigene1 into all three variants.
No cDNA was detected for full length, or any alternatively spliced transcripts for
minigene1 in SH-SY5Y cells or differentiated THP-1 cells (Figure 13.A). The fact that
no bands of the correct size were detected in these cells was unanticipated. Full-length, as
well as Δ7 CPB2 mRNA has been previously reported in both of these cell lines (89). In
fact, Δ7 CPB2 mRNA was reported to be a dominant species present in total RNA
samples from SH-SY5Y cells (89). It is evident that the cells were either not transfected
or were transfected at too low an efficiency.
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The results from the RT-PCR analysis also clearly reveal that minigene2 was
detected in every cell type tested as full length minigene2. The fact that full length
minigene2 was detected in HepG2 and SH-SY5Y cells is in accordance with what has
been previously published for both of these cell lines (89). However, no cDNA was
detected for Δ11 minigene2 in any cell type tested. Of all the cell types examined, the
only one that endogenously expresses Δ11 is SH-SY5Y. The fact that no cDNA for Δ11
was detected in this cell line is somewhat unexpected since it has been previously
reported as a dominant species present in this cell type (89). It is possible that the Δ11
variant was present at too low a proportion to be detected, although this was not borne
out by our subsequent quantitative analysis (see below). Another explanation would be
that the small difference in amplicon size (50 bp) could not be resolved by agarose gel
electrophoresis performed under these conditions. A higher concentration of agarose,
separation at a lower voltage, and loading a smaller quantity of PCR product on the gel
may have revealed the presence of the Δ11 amplicon.

4.3 Quantification of Endogenous and Minigene CPB2 mRNA in Several Cell Types
via Real Time RT-PCR

Since RT-PCR proved not sensitive enough to detect some of the alternatively
spliced transcripts produced by the minigenes and is only semi-quantitative, we opted for
a more sensitive technique, real time RT-PCR to attain a more quantitative measure of
the alternative splicing events that are occurring within each cell type of interest. Real
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time RT-PCR is a highly sensitive assay and can detect very low copy numbers of
transcripts from a cellular heterogeneous mixture. However, since it is such a sensitive
technique, it is also often susceptible to genomic DNA (gDNA) contamination during
carryover in RNA extractions. To control for this possibility, no RT (NRT) controls were
performed alongside samples to ensure amplification was genuinely from cDNA. In
addition, no template control (NTC) reactions were also performed to ensure that the
water and reagents used were free from contamination.
Previously, a study by Matsumoto and colleagues (83) reported the first incidence
of an alternatively spliced brain-specific TAFI, HBCPB (aka Δ7+11). They originally
detected the alternatively spliced variant in the brain (hippocampus), and also later
reported its existence in human serum and cerebrospinal fluid (84). These studies were
performed with the use of an antibody raised against the novel 14-residue carboxyl
terminus that is encoded as a result of the Δ11 alternative splicing event. In addition, a
second study performed by Cagliani and colleagues (88), reported a second finding of an
alternatively spliced CPB2 mRNA which only lacked exon 7 (Δ7), and was identified in
HepG2 cells and liver samples. They also reported that they did not detect any Δ11
alternatively spliced species within the liver (88). In a later study by Lin and colleagues
(89), the pattern of alternatively spliced CPB2 transcripts was semi-quantitatively
investigated in various tissues, and vascular and immune cells. From this study, a third
novel CPB2 mRNA transcript was discovered that lacked exon 7 and exon 8 (Δ7+8) in
HepG2 cells.
In this study, the results from the real time RT-PCR analysis confirmed our
original hypothesis that alternative splicing of CPB2 is regulated in a cell specific
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manner. We were able to show that there are several alternatively spliced variants in
every cell type examined along with full length CPB2, and the abundance of every
transcript varies between cell types. This is the first study to quantitatively demonstrate
the pattern of alternatively spliced CPB2 transcripts within various vascular and immune
cells.
In HepG2 cells, the full length CPB2 transcript is in far larger amounts than the
alternatively spliced variants, of which, Δ7, Δ7+8, and Δ11 were present. The expression
of Δ7 and Δ7+8 CPB2 transcripts within HepG2s is in accordance with what has been
previously published for this cell line (88, 89). However, this is the first report of Δ11
CPB2 being expressed in HepG2 cells. This finding contrasts previous reports (88, 89)
that did not detect Δ11 CPB2 within HepG2 cells. A possible reason why it was not
previously detected could be due to the fact that only RT-PCR analysis of HepG2s for the
Δ11 variant was performed, and this may not have been sensitive enough to detect its low
copy number. Note that less that 1% of the total HepG2 transcripts contain the Δ11
splicing event (Table 3.1). Another possibility may be that the expression of the Δ11
variant only takes place under certain, as-yet undefined, environmental conditions (such
as a different source of serum), which took place during this study.
In SH-SY5Y cells, the Δ7 CPB2 transcript is more abundant than the full length
and Δ11 CPB2 transcripts. The expression of full length, Δ7 and Δ11 CPB2 transcripts in
these cells (89) was confirmed in this study. No Δ7+8 CPB2 mRNA was detected in SHSY5Ys in this study. In differentiated THP-1 cells, the full length CPB2 transcript is
more abundant than the Δ7 and Δ7+8 CPB2 transcripts. The expression of full length and
Δ7 CPB2 transcripts within differentiated THP-1 cells (89) was confirmed in this study.
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Expression of the Δ7+8 CPB2 variant in differentiated THP-1 cells was also confirmed.
CPB2 mRNA corresponding to the Δ11 variant was not investigated in differentiated
THP-1 cells in this study.
What the current study crucially provides that distinguishes it from our previous
work is quantitative information about the relative abundance of the various alternatively
spliced forms of the CPB2 transcript. From these findings, it is clear that alternative
splicing leading to variant forms of the TAFI protein is much more prevalent in nonhepatic cells than it is in HepG2 cells. These findings may reflect the importance of
putatively novel functions of the TAFI variants in the non-hepatic cell types.
Alternatively, it may reflect the considerably lower basal expression of the CPB2 mRNA
in these cell types, such that a baseline frequency of alternative splicing makes these
events more prevalent on a relative scale. Importantly, we previously demonstrated (89)
that the alternatively spliced CPB2 transcripts are not subject to nonsense-mediated
decay, bolstering the idea that the transcripts encode functional proteins.
The results from the real time RT-PCR analysis for minigene1 demonstrated that
it does not recapitulate the frequency pattern of alternative splicing in any of the cell
types tested. As previously stated, the pattern of alternative splicing is regulated in a cell
specific manner and the even the abundance of each transcript varies between cell types.
However, with respect to minigene1, the frequency of the different splicing events does
not vary much between cell types. Minigene1 was preferentially spliced to produce the
Δ7 minigene1 variant, followed by full length, then the Δ7+8 minigene1 variant within
every cell type tested, except differentiated THP-1 (Δ7 minigene1 was followed by the
Δ7+8 minigene1 variant, then full length minigene1). With respect to minigene2, there is
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a different trend produced than what was observed for minigene1 alternative splicing
events. In every cell type tested, full length minigene2 was much more abundant than
Δ11 minigene2, except for in SH-SY5Y cells. Nonetheless, with either minigene, there is
very poor concordance in alternative splicing frequencies between the endogenous and
minigene-encoded transcripts.
From this study, we have gained a quantitative understanding of the cell specific
alternative splicing regulation of CPB2 in various immune and vascular cell types. This
knowledge will assist in the designing of future experiments to determine what cell
specific factors are regulating the alternative splicing pattern of CPB2, as well as
hopefully deduce the mechanism by which alternative splicing takes place in these cells.
The data also provides an impetus to examine what function, if any, is possessed by the
TAFI variants arising from alternative splicing.
Future work should be aimed at deducing the cis-acting elements within the premRNA of CPB2 that stimulate the alternative splicing pathway instead of the constitutive
pathway of splicing, and the trans-acting factors that initiate this as well. There are
several cis-acting regulatory splicing sequences that must be recognized by the splicing
machinery in order for splicing to occur correctly. These cis-splicing regulatory
sequences can be located within the exon or intron sequence of the pre-mRNA. Some
examples of universal regulatory splicing sequences include: the 5’ and 3’ splice sites
which define the beginning and the end of the intron sequence, the intron branch point
sequence, and a polypyrimidine tract located upstream of the 3’ splice site (91).
Furthermore, there are several cis-acting regulatory sequences within the exon and intron
sequences, which can alter the path and rate of alternative splicing when bound by their
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appropriate trans-acting factor proteins. Some examples of these cis-acting regulatory
sequences include: exon splicing enhancers (ESEs), exon splicing silencers (ESSs), intron
splicing enhancers (ISEs), and intron splicing silencers (ISSs) (91).
Enhancer and silencer sequences within the pre-mRNA that are bound by their
trans-acting factor proteins have the ability to alter splice site selection by selecting for or
repressing a specific splice site (98). Enhancer sequences within exons are often bound
by proteins part of the Serine/Arginine-rich (SR) splicing factor protein family (98).
These proteins contain two specific domains, which are important to their function as
splicing factors. The first domain is an RNA-Recognition-Motif (RRM), which is
required for binding to the cis-regulatory sequence on the pre-mRNA target (98). The
second is an RS domain, which is located at its carboxyl terminal, and is rich in arginine
and serine dipeptides (98). The RS domain of SR proteins is important for protein-protein
interactions during splicing (98). SR proteins that are bound to their respective ESE
sequences can promote the recognition of an exon by the splicing machinery, and can
also recruit further splicing machinery to the splice site (98).
Silencer sequences within introns are often bound by proteins part of the
heterogeneous nuclear ribonucleoprotein (hnRNP) family (98). HnRNPs also have RRMs
to bind to target pre-mRNAs; however, they use arginine/glycine rich domains instead of
RS domains to interact with other proteins during splicing (98). HnRNPs can promote
exon skipping by binding to the pre-mRNA sequence and causing the mRNA structure to
change in a way that isolates the silenced exon, so that it is skipped by the splicing
machinery (98). Another method by which hnRNPs can silence an exon is by binding to a
high affinity ESS sequence on a pre-mRNA and inducing recruitment of additional
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hnRNPs to bind to the region (98). Excessive binding of hnRNPs can block the binding
of SR proteins to ESE regions, and can even displace previously bound SR proteins to
ESE sequences (98).
Through bioinformatic analysis of the CPB2 gene, possible cis-acting regulatory
sequences of alternative splicing can be identified. Once the location of these sequences
are known, mutations can be inserted into the minigenes at these locations to study their
effects on the alternative splicing pattern of CPB2. Furthermore, analysis of potential
trans-acting factor proteins can also be investigated. Potential trans-acting regulatory
proteins can be assessed for their ability to modulate the alternative splicing pattern of
CPB2 by cloning them into expression vectors and overexpressing them within the cell,
followed by monitoring their effect on the type of alternatively spliced transcripts
produced, as well as their abundance levels within each cell type. The specific population
and abundance of SR proteins and hnRNPs within a particular cell type could determine
the output of CPB2 splicing events as well. By identifying the cis-acting regulatory
sequences and their associated trans-acting factor proteins within the pre-mRNA of
CPB2, the mechanism by which alternative splicing of CPB2 takes place within each cell
type can start to emerge and be understood.
Furthermore, alternative splicing can also be regulated in a tissue specific (99),
developmental stage specific (100), or even by environmental factors such as hormones,
for example estrogen (101). Previous studies have demonstrated that CPB2 expression
can also be regulated by the presence of specific inflammatory cytokines (IL-1β and Il-6)
(16), as well as by the particular stage of differentiation of THP-1 and Dami cells (82).
Thus, future experiments should be aimed at investigating the possible effects that these
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various alternative stimuli can induce on the alternative splicing pathway of CPB2 in
order to further our understanding of the mechanism by which alternative splicing of
CPB2 takes place.
Although there are various published examples of minigenes that are capable of
reproducing the alternative splicing pattern created by the natural gene (93, 94, 95, 96),
the minigenes constructed within this study were not successful in this aim quantitatively.
In this study, minigene1 was preferentially spliced to produce Δ7 minigene1 variant
instead of the full length minigene1 variant in every cell type examined. The preferential
skipping of exon 7 in minigene1 could be due to missing cis-regulatory sequences within
the intronic region between exon 6 and exon 7 of minigene1 that occur naturally in the
full length transcript. Since the minigene only contains a small portion of the intronic
region that innately resides between the exons of CPB2, this could result in an altered
ratio of enhancer to silencer sequences present in the minigene pre-mRNA transcript,
which favors silencing and exclusion of exon 7 that does not normally occur during the
processing of the full length transcript.
Moreover, the preferential skipping of exon 7 in minigene1 could be attributed to
the production of an altered secondary structure by the pre-mRNA transcript of
minigene1 that differs from the secondary structure created by the full length transcript.
This change in RNA secondary structure could attract hnRNP splicing regulatory proteins
to bind to ISS sequences within the pre-mRNA of minigene1 and cause a splice site that
is normally recognized by the spliceosome to be looped out, resulting in increased
preferential skipping of exon 7 instead of its inclusion in the mature mRNA transcript.
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Modified minigenes that contain additional intronic sequences may alleviate the nonrepresentative splicing pattern seen in the existing minigenes.
A final possibility is that the level of expression of the transcripts from the
minigenes, which was much higher than for the endogenous gene, resulted in aberrant
usage of splice donor and acceptor sites; some factors required for inclusion of all the
exons in this transcript may be limiting. The level of expression of the minigene
transcripts could be tuned by utilizing a less powerful promoter, or by using a
doxycycline-inducible promoter and titrating the concentration of doxycycline in the
medium.
Most pre-mRNA transcripts contain multiple ESE, ESS, ISS, ISE sequences,
which are bound by unique combinations of splicing regulatory proteins, such as SR
proteins and hnRNPs. Thus, the mature mRNA that results from alternative splicing
events is the product of the combination of various cis-acting regulatory sequences that
induce positive and negative effects on a pre-mRNA transcript through the binding of
splicing regulatory proteins, particularly SR proteins and hnRNPs. The change in the
presence or absence of any of these factors can alter the decision by the spliceosome to
include or exclude any portion of the pre-mRNA transcript in the mature mRNA
transcript in a cell specific manner.
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4.4 Identification of Full Length and Alternatively Spliced TAFI Variants via
Metabolic Labeling

To detect full length and alternatively spliced TAFI protein, metabolic labeling
was employed. Full length TAFI (~ 63 kDa) was successfully identified in the medium of
transfected HepG2 and BHK cells via metabolic labeling. This result was anticipated due
to the fact that the liver is the main source of plasma TAFI (26). In addition, while BHK
cells do not endogenously express TAFI, the cells are readily transfected and have been
used for heterologous expression of recombinant TAFI (30).
Full length TAFI immunoprecipitated with the monoclonal anti-myc antibody was
not detected in the medium of BHK cells, although it was detected in the medium of
transfected HepG2 by this method; moreover, full length TAFI immunoprecipitated with
the polyclonal anti-TAFI antibody was also detected in the medium of BHK cells. A
possible explanation for this occurrence could be that 90 hours of exposure was not long
enough to detect the TAFI present in that sample. It is also possible that there was a
technical issue with the immunoprecipitation of this sample. Also, no alternatively
spliced TAFI variants were detected in the medium of either cell line, as expected based
on previous results (89). It remains possible that the lack of detection of these variants in
the BHK media was due to the same technical issue that may have affected the full-length
variant. It must be noted, however, that no mature Δ7 variant was detected in the lysates
of the BHK cells.
Full length TAFI in its glycosylated mature, secretable and hypoglycosylated
immature forms were also detected in the lysates of both HepG2 and BHK cell lines. In

	
  

104

addition, Δ7 TAFI, slightly smaller in MW than the hypoglycosylated immature full
length TAFI form, was also detected in the lysates of HepG2 cells for the first time.
Crucially, fully glycosylated Δ7 could not be detected. The Δ11 TAFI and Δ7+11 TAFI
variants were not detected at all in the lysates of HepG2 cells, in contrast to our previous
findings (89). Clearly, additional optimization is required to detect these variants, which
should be present as a result of overexpression of a cDNA specifically encoding them.
Although mRNA encoding the Δ11 and Δ7+11 TAFI variants has not been detected
previously in the liver, it has been detected in the hippocampus region of the brain,
human serum and cerebrospinal fluid (83, 84). Future experiments should be repeated in
the SH-SY5Y cell line in which endogenous mRNA encoding these variants is likely to
be expressed.
Pulse-chase experiments clearly showed the appearance of the mature, fully
glycosylated form of TAFI in the lysates coincident with appearance of secreted TAFI in
the medium. For the Δ7 variant, by contrast, there was no band of the expected size for
the mature, fully glycosylated form either in the lysates or the medium. These findings
are in support of our hypothesis (89) that the variants arising from alternative splicing are
retained in the endoplasmic reticulum (ER) as incompletely glycosylated species and thus
cannot proceed through the secretory pathway. We suspect that some aspect of the
folding process is aberrant when the sequences encoded by the alternatively spliced exons
are missing such that processing of nascent glycans necessary for ER exit does not occur.
Currently, the function of the alternatively spliced TAFI variants is unknown.
Previous studies have shown that these variants cannot be activated by thrombinthrombomodulin, the main physiological activator of TAFI, and thus do not possess
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TAFIa carboxypeptidase activity (89, 29). In addition, they are not secreted from the cell
and therefore, they cannot participate in hemostasis (89). From these observations, one
could speculate that the production of alternatively spliced transcripts may be a process
that the cell undergoes in order to down regulate the amount of fully functional TAFI
present in circulation at any given time. Certainly, our quantitative experiments show that
exon 7 is skipped in a considerable proportion of the CPB2 transcripts in non-hepatic cell
types which, in addition to the lower amount of CPB2 mRNA present in these cells, is in
keeping with the lower levels at which they express TAFI protein.
Alternatively, the production of alternatively spliced transcripts could also result
in related TAFI proteins that have alternate functions within the cell. Support for this
premise can be found in the study by Matsumoto and colleagues, where HBCPB (i.e.
Δ7+11 TAFI) was reported to have endopeptidase activity towards β-APP and Aβ1-42
(83). Since the endopeptidase activity of only the Δ7+11 TAFI variant was examined in
this prior study, it would be advantageous to test the other alternatively spliced TAFI
variants for endopeptidase activity towards β-APP and Aβ1-42 to see if they also share this
alternate function. It remains to be conclusively demonstrated that HBCPB directly acts
as a peptidase; there is no sequence similarity between TAFI and endopeptidases, and the
Δ11 variant even lacks a Glu residue that is absolutely required for carboxypeptidase
activity (89). The availability of the myc-tagged TAFI variants will allow this question to
be addressed definitively.
Further evidence supporting the notion that the alternatively spliced transcripts
may have an alternate intracellular role comes from examining the crystal structure of the
TAFI protein produced by the alternative splicing events. For example, alternative
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splicing of exon 7 results in the loss of 37 amino acids, and deletion of a β- strand and
parts of 2 α-helices encoded by exon 7 (102). Also, alternative splicing that leads to the
deletion of the 52 bp within exon 11 results in the loss of a flexible loop that attaches a βsheet to an α-helix segment (102). These deletions, alone or jointly, would produce a
protein with a significantly altered 3-D structure, which would thus also affect its
functional properties. Due to the substantial amount of deletions within the amino acid
sequence, the protein produced by the alternative splicing events is likely to be misfolded
and thus retained within the ER. This alternative localization pattern for the alternatively
spliced TAFI proteins could potentially result in a new function for these proteins within
the endoplasmic reticulum. For example, they could function as molecular chaperones
assisting in protein folding in the ER.
To investigate the possibility that alternatively spliced TAFI variants can act as
molecular chaperones within the endoplasmic reticulum, affinity chromatography could
be used to capture alternatively spliced TAFI variants in complex with an interacting
protein via the His tag on the recombinant TAFI proteins. To determine the identity of the
proteins, mass spectrometry could be employed. By determining the molecules that the
alternatively spliced TAFI proteins interact with, their biological function within the cell
can begin to be determined. From these findings, future experiments can be designed to
advance the understanding of the mechanisms by which these proteins interact. A
tempting hypothesis is that TAFI variants are not themselves the endopeptidase that
processed β-APP and/or Aβ1-42, but rather act as chaperones or cofactors for the bona fide
endopeptidases that do perform these functions.
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4.5 Conclusion

In conclusion, this study quantitatively determined the extent of CPB2 pre-mRNA
alternative splicing events occurring in various vascular and immune cells via real time
RT-PCR analysis. The minigene constructs produced in this study could be spliced into
the full length and alternatively spliced CPB2 transcripts predicted as demonstrated by
the RT-PCR and real time RT-PCR analysis. However, neither one was successful in
recapitulating, in a quantitative sense, the alternative splicing pattern of CPB2 by the cell
specific regulated mechanism that occurs endogenously. Future work should be aimed at
deducing the cis-acting regulatory sequences within CPB2 pre-mRNA and the splicing
regulatory proteins that govern the splicing behaviour of CPB2 in different cell types. In
addition, future experiments using different environmental stimuli to assess their effect
on the alternative splicing pattern of CPB2 will also provide insight into the mechanism
by which alternative splicing is initiated to regulate CPB2 gene expression under
different environmental conditions. Overall, this information will give us a better
understanding of the unique sequences and splicing regulatory proteins involved in
alternative splicing of CPB2, as well as demonstrate the specific environmental stimuli
that induce the alternative splicing pathway of CPB2 during different cellular conditions.
This study also identified protein corresponding to the Δ7 TAFI variant within the
lysates of HepG2 cells via metabolic labeling. Since the alternatively spliced Δ7 TAFI
variant was not secreted from the cell, this reconfirms the notion that alternatively spliced
TAFI variants do not participate in hemostasis. Currently, the biological function of the
alternatively spliced transcripts remains unknown. One prior study demonstrated that the
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Δ7+11 TAFI variant possessed endopeptidase activity towards β-APP. Future
experiments should be aimed at verifying this functional property of the Δ7+11 TAFI
variant, as well as test the ability of the other alternatively spliced TAFI variants for
endopeptidase activity towards β-APP. In addition, future work aimed at deducing the
interacting partners of these alternatively spliced intracellular TAFI variants will give us
insight into the unique roles that these TAFI variants possess within each cell type.
Overall, the knowledge gained from these findings will help us achieve a greater
understanding of the functional and regulatory significance of the alternative splicing
mechanisms that govern CPB2 gene expression.
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